Unnamed: 0,title,date,stock,sentiment
664585.0,Incyte To Highlight Data From Interim Analysis Of Phase 2 OPTIC Trial At ASCO,2020-05-29 08:16:00-04:00,INCY,positive
664586.0,"Shares of several healthcare companies are trading higher amid market strength. Strength potentially related to coronavirus efforts including testing, vaccine development and treatment measures from several names in the sector.",2020-05-28 12:33:00-04:00,INCY,positive
664587.0,Bristol-Myers Analyst Says 'Big 7' Pipeline Assets Hold $15B In Peak Sales Potential,2020-05-27 11:45:00-04:00,INCY,positive
664588.0,Incyte and MorphoSys Announce the Validation of the European Marketing Authorization Application for Tafasitamab,2020-05-20 14:02:00-04:00,INCY,neutral
664589.0,10 Biggest Price Target Changes For Tuesday,2020-05-19 08:01:00-04:00,INCY,neutral
664590.0,"Cantor Fitzgerald Maintains Neutral on Incyte, Raises Price Target to $100",2020-05-19 07:28:00-04:00,INCY,neutral
664591.0,"Incyte Highlights Oral, Poster Discussions At ASCO At Virtual ASCO Starting May 29",2020-05-14 12:22:00-04:00,INCY,neutral
664592.0,"Morgan Stanley Maintains Equal-Weight on Incyte, Raises Price Target to $95",2020-05-12 08:19:00-04:00,INCY,neutral
664593.0,"The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500",2020-05-07 07:41:00-04:00,INCY,negative
664594.0,BZ NOTE: Tabrecta Is Molecule Discovery By Incyte Scientists,2020-05-06 14:42:00-04:00,INCY,positive
664595.0,Incyte Issues Press Release Highlighting FDA Approval Of Novartis' Tabrecta,2020-05-06 14:41:00-04:00,INCY,positive
664596.0,"BMO Capital Maintains Market Perform on Incyte, Raises Price Target to $90",2020-05-06 11:20:00-04:00,INCY,neutral
664597.0,Incyte shares are trading lower after JP Morgan analysts downgraded the company's stock from Overweight to Neutral.,2020-05-06 08:39:00-04:00,INCY,neutral
664598.0,JP Morgan Downgrades Incyte to Neutral,2020-05-06 05:17:00-04:00,INCY,positive
664599.0,"The Daily Biotech Pulse: Bio-Rad's Coronavirus Test Gets EUA, Beat-And-Raise Quarter From GenMark, Adverum's Positive Gene Therapy Readout",2020-05-05 08:00:00-04:00,INCY,positive
664600.0,"Incyte Q1 Adj.  EPS $(2.860) Does Not Compare To $0.610 Estimate, Sales $569.000M Beat $555.720M Estimate",2020-05-05 07:04:00-04:00,INCY,neutral
664601.0,"Earnings Scheduled For May 5, 2020",2020-05-05 04:53:00-04:00,INCY,neutral
664602.0,The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace,2020-05-03 08:45:00-04:00,INCY,neutral
664603.0,"Benzinga's Top Upgrades, Downgrades For April 29, 2020",2020-04-29 09:32:00-04:00,INCY,positive
664604.0,"Morgan Stanley Downgrades Incyte to Equal-Weight, Announces $94 Price Target",2020-04-29 06:23:00-04:00,INCY,neutral
664605.0,"The Daily Biotech Pulse: Pfizer Earnings, Roche's Spinal Muscular Dystrophy Treatment, Moderna COVID-19 Vaccine Update",2020-04-28 07:36:00-04:00,INCY,neutral
664606.0,Stocks That Hit 52-Week Highs On Monday,2020-04-27 10:21:00-04:00,INCY,neutral
664607.0,"The Daily Biotech Pulse: FDA Approves Sanofi's Meningococcal Vaccine, Pluristem Secures $54M In Funding For COVID-19 Treatment, Oric Pharma Prices IPO",2020-04-24 08:38:00-04:00,INCY,positive
664608.0,Stocks That Hit 52-Week Highs On Thursday,2020-04-23 10:41:00-04:00,INCY,neutral
664609.0,"The Daily Biotech Pulse: FDA Nod For Immunomedics, Lilly's Solid Q1 Beat, Predictive Oncology Restructures Debt",2020-04-23 07:53:00-04:00,INCY,negative
664610.0,"UPDATE: Incyte Said Phase 3 REACH2 Data Showed Jakafi Improves Outcomes, Showed Significantly Greater Overall Response Rate",2020-04-22 17:54:00-04:00,INCY,positive
664611.0,Incyte Shares Quiet After Hours Following Earlier Press Release Highlighting Publishing Of Pivotal REACH2 Study Data On Jakafi Against Acute Graft-Versus-Host Disease In New England Journal Of Medicine,2020-04-22 17:53:00-04:00,INCY,positive
664612.0,"Oppenheimer Maintains Outperform on Incyte, Raises Price Target to $112",2020-04-21 08:22:00-04:00,INCY,neutral
664613.0,"The Daily Biotech Pulse: Applied DNA Begins Validating COVID-19 Test, Cara's Positive Readout, Novan Explores Strategic Alternatives",2020-04-21 08:19:00-04:00,INCY,positive
664614.0,Stocks That Hit 52-Week Highs On Monday,2020-04-20 10:25:00-04:00,INCY,neutral
664615.0,"FDA Approves Incyte's Pemazyre  as First Targeted Treatment for Adults with Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma",2020-04-19 11:14:00-04:00,INCY,positive
664616.0,Incyte Announces Initiation Of Phase 3 RUXCOVID Study Evaluating Ruxolitinib (Jakafi) As A Treatment For Patients With Coronavirus Associated Cytokine Storm,2020-04-17 15:48:00-04:00,INCY,neutral
664617.0,Stocks That Hit 52-Week Highs On Friday,2020-04-17 10:19:00-04:00,INCY,neutral
664618.0,Shares of several healthcare companies are trading higher as markets gain on positive coronavirus outlook. Other potential positive sector catalysts include demand for therapies and medical supplies amid the coronavirus pandemic.,2020-04-14 10:59:00-04:00,INCY,positive
664619.0,"Oppenheimer Maintains Outperform on Incyte, Raises Price Target to $90",2020-04-07 08:44:00-04:00,INCY,neutral
664620.0,Shares of several healthcare companies are trading higher as markets gain amid optimism that coronavirus cases in several US hotspots may be peaking. A sooner peak could mean a sooner return to economic activity.,2020-04-06 09:42:00-04:00,INCY,positive
664621.0,Incyte Announces First Presentation of Phase 3 Data from the TRuE-AD Program of Ruxolitinib Cream at the Revolutionizing Atopic Dermatitis Virtual Symposium,2020-04-05 08:24:00-04:00,INCY,neutral
664622.0,"The Daily Biotech Pulse: Fate Therapeutics Inks Cell Therapy Deal With J&J, Zentalis IPO",2020-04-03 07:36:00-04:00,INCY,neutral
664623.0,Incyte To Initiate Phase 3 Clinical Trial Of Ruxolitinib As A Treatment For Patients With Coronavirus- Associated Cytokine Storm,2020-04-02 17:09:00-04:00,INCY,neutral
664624.0,"Morgan Stanley Upgrades Incyte to Overweight, Raises Price Target to $90",2020-04-01 09:43:00-04:00,INCY,negative
664625.0,"Shares of several healthcare companies are trading lower, selling off from this week's strength. While the US stimulus package boosted economic optimism, demand concerns still exist amid the coronavirus outbreak.",2020-03-27 10:58:00-04:00,INCY,positive
664626.0,10 Stocks To Buy With Low Debt And High Liquidity,2020-03-27 08:15:00-04:00,INCY,negative
664627.0,"The Daily Biotech Pulse: Milestone Pharma Flunks Late-Stage Study, CytomX Strikes Cancer Drug Collaboration, BARDA Grant For GenMark's COVID-19 Test",2020-03-24 08:20:00-04:00,INCY,negative
664628.0,"The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection",2020-03-19 07:37:00-04:00,INCY,neutral
664629.0,Lilly Receives FDA Breakthrough Therapy Designation for Baricitinib for the Treatment of Alopecia Areata,2020-03-16 06:46:00-04:00,INCY,neutral
664630.0,Shares of several healthcare companies are trading higher as the market rebounds following Thursday's selloff. NOTE: Since the coronavirus outbreak the healthcare sector has been extremely volatile.,2020-03-13 09:29:00-04:00,INCY,positive
664631.0,Stocks That Hit 52-Week Lows On Thursday,2020-03-12 12:10:00-04:00,INCY,negative
664632.0,"Credit Suisse Maintains Neutral on Incyte, Lowers Price Target to $81",2020-03-11 08:55:00-04:00,INCY,positive
664633.0,"The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment",2020-03-11 08:03:00-04:00,INCY,positive
664634.0,"The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index",2020-03-10 09:19:00-04:00,INCY,negative
664635.0,Shares of several healthcare  companies are trading lower. Movement appears market-related as markets continue to dip amid the global coronavirus outbreak and OPEC failing to reach production agreement.,2020-03-09 10:55:00-04:00,INCY,neutral
664636.0,Shares of several healthcare companies are trading lower. Movement appears market related as markets continue to dip amid the global coronavirus outbreak.,2020-03-06 09:11:00-05:00,INCY,neutral
664637.0,"The Daily Biotech Pulse: Trevana Pain Drug Resubmission Accepted For Review, Can-Fite To Explore Treatment For COVID-19",2020-03-05 08:05:00-05:00,INCY,negative
664638.0,"The Daily Biotech Pulse: Takeda Jumps Into The COVID-19 Fray, Exact Sciences Buys Cancer Diagnostics Companies",2020-03-04 07:37:00-05:00,INCY,negative
664639.0,Morphosys And Incyte Announce Antitrust Clearance Of Global Collaboration And License Agreement For Tafasitamab; Agreement Becoming Effective Triggers $750M Upfront Payment By Incyte To Morphosys,2020-03-03 16:05:00-05:00,INCY,positive
664640.0,Incyte shares are trading higher after the company reported primary and secondary endpoints from Phase 3 TRuE-AD study was met.,2020-02-19 10:53:00-05:00,INCY,positive
664641.0,Incyte Announces Topline Results From Phase 3 TRuE-AD Program Evaluating Ruxolitinib Cream In Patients With Atopic Dermatitis; PRimary And Secondary Endpoints Met In Both TRuE-AD1 And TRuE-AD2,2020-02-19 07:32:00-05:00,INCY,neutral
664642.0,Incyte shares are trading higher after the company reported better-than-expected Q4 EPS and sales results.,2020-02-13 15:30:00-05:00,INCY,positive
664643.0,"The Daily Biotech Pulse: Deciphera Cancer Drug Gets Priority Review, Fast Track Designation For Soligenix, Revolution Medicines IPO",2020-02-13 08:05:00-05:00,INCY,negative
664644.0,Incyte Sees FY20 Sales $1.980B-$2.055B Vs. $2.45B Est.,2020-02-13 07:10:00-05:00,INCY,neutral
664645.0,"Incyte Q4 EPS $0.65 Beats $0.57 Estimate, Sales $579.389M Beat $575.49M Estimate",2020-02-13 07:06:00-05:00,INCY,neutral
664646.0,"Earnings Scheduled For February 13, 2020",2020-02-13 04:27:00-05:00,INCY,neutral
664647.0,"The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data",2020-02-12 09:18:00-05:00,INCY,positive
664648.0,Lilly and Incyte Announce Positive Top-Line Results from the North American Phase 3 Study (BREEZE-AD5) of Oral Selective JAK Inhibitor Baricitinib in Patients with Moderate- to Severe Atopic Dermatitis,2020-02-12 05:10:00-05:00,INCY,positive
664649.0,"The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology",2020-02-11 07:23:00-05:00,INCY,positive
664650.0,Incyte Announces FDA Acceptance and Priority Review of NDA for Capmatinib for Advanced Non-Small Cell Lung Cancer,2020-02-11 05:05:00-05:00,INCY,negative
664651.0,The Week Ahead In Biotech: SMID-Cap Earnings In The Spotlight,2020-02-09 15:22:00-05:00,INCY,neutral
664652.0,Shares of several healthcare and biotech companies are trading higher as unconfirmed reports of progress towards a coronavirus treatment raise investor sentiment amid the virus outbreak. NOTE: The WHO played down these reports and said there are no known treatments.,2020-02-05 09:47:00-05:00,INCY,positive
664653.0,B of A Securities Reinstates Neutral on Incyte,2020-02-04 06:44:00-05:00,INCY,positive
664654.0,Stocks That Hit 52-Week Lows On Friday,2020-01-31 11:00:00-05:00,INCY,negative
664655.0,Eli Lilly Reports Top-Line Results From BREEZE-AD5 Phase 3 Study Of Oral Selective JAK Inhibitor In Patients With Moderate To Severe Atopic Dermatitis,2020-01-30 06:15:00-05:00,INCY,negative
664656.0,Incyte Announces TRuE-AD2 Pivotal Trial Of Ruxolitinib Cream Met Primary Endpoint In Patients with Atopic Dermatitis,2020-01-28 07:30:00-05:00,INCY,neutral
664657.0,"The Daily Biotech Pulse: Acceleron's Positive Data Readout, Surface Oncology Gets Nod For Pushing 2 Antibodies Into Clinics",2020-01-28 07:12:00-05:00,INCY,positive
664658.0,Eli Lilly and Incyte's Phase 3 BREEZE-AD4 Study Met its Primary Endpoint,2020-01-27 06:47:00-05:00,INCY,neutral
664659.0,"Cantor Fitzgerald Maintains Neutral on Incyte, Raises Price Target to $83",2020-01-23 08:16:00-05:00,INCY,neutral
664660.0,Incyte shares are trading higher after JMP Securities maintained an Outperform rating and raised the price target from $99 to $121.,2020-01-14 11:05:00-05:00,INCY,positive
664661.0,"JMP Securities Maintains Outperform on Incyte, Raises Price Target to $121",2020-01-14 11:03:00-05:00,INCY,positive
664662.0,Incyte Announces European Medicines Agency Validation Of Its Marketing Authorization Application For Pemigatinib In Patients With Cholangiocarcinoma,2020-01-07 06:01:00-05:00,INCY,neutral
664663.0,"Morgan Stanley Maintains Equal-Weight on Incyte, Lowers Price Target to $83",2020-01-06 09:13:00-05:00,INCY,negative
664664.0,53 Biggest Movers From Friday,2020-01-06 05:30:00-05:00,INCY,neutral
664665.0,"UPDATE: JMP Reiterates Market Outperform On Incyte, Lowers Target To $99 Notes 'we continue to recommend shares of Incyte since ruxolitinib (rux) remains well positioned to generate $1.66B in U.S. sales in 2019'",2020-01-03 13:09:00-05:00,INCY,positive
664666.0,30 Stocks Moving In Friday's Mid-Day Session,2020-01-03 12:29:00-05:00,INCY,neutral
664667.0,"Benzinga's Top Upgrades, Downgrades For January 3, 2020",2020-01-03 11:33:00-05:00,INCY,positive
664668.0,"UPDATE: Credit Suisse Maintains Neutral On Incyte, Lowers Target To $86 After Co's Itacitinib Results Notes 'Given this result, we have removed all credit for itacitinib in our INCY mode (we only modeled S-N aGVHD) or approximately $4/share (at 65% PoS)'",2020-01-03 10:54:00-05:00,INCY,positive
664669.0,"UPDATE: Cantor Fitzgerald On Incyte Notes 'We still remain Neutral as we think Jakafi is doing very well commercially. On the other hand, we look for more pipeline opportunities to add to the base business over the next 12 mos'",2020-01-03 10:47:00-05:00,INCY,positive
664670.0,"UPDATE: Cantor Fitzgerald Maintains Neutral On Incyte, Lowers Target To $65 Notes 'We are cautious on chronic opportunity of itacitinib, though acute and chronic do have some pathological differences'",2020-01-03 10:46:00-05:00,INCY,positive
664671.0,"UPDATE: Goldman On Incyte Notes 'we are constructive on the dermatology franchise (topical ruxolitinib in atopic dermatitis and vitiligo) which represents optionality (not included in model), with Ph3 TRuE-AD data for the former in 1H20'",2020-01-03 10:38:00-05:00,INCY,neutral
664672.0,"UPDATE: Goldman Maintains Buy On Incyte, Lowers Target To $107, Keeps On Americas Conviction List Notes 'Ph3 GRAVITAS-301 fails; Looking to atopic dermatitis in 1H20'",2020-01-03 10:37:00-05:00,INCY,negative
664673.0,"Goldman Sachs Maintains Buy on Incyte, Lowers Price Target to $107; Keeps On Americas Conviction List",2020-01-03 09:46:00-05:00,INCY,negative
664674.0,"Credit Suisse Maintains Neutral on Incyte, Lowers Price Target to $86",2020-01-03 09:07:00-05:00,INCY,positive
664675.0,"Oppenheimer Maintains Outperform on Incyte, Lowers Price Target to $96",2020-01-03 08:45:00-05:00,INCY,negative
664676.0,10 Biggest Price Target Changes For Friday,2020-01-03 08:31:00-05:00,INCY,neutral
664677.0,"BMO Capital Maintains Market Perform on Incyte, Lowers Price Target to $74",2020-01-03 08:16:00-05:00,INCY,negative
664678.0,Incyte shares are trading lower after itacitinib did not statistically improve overall response rate or non-relapse mortality compared to placebo in its Phase 3 study.,2020-01-03 08:14:00-05:00,INCY,negative
664679.0,"The Daily Biotech Pulse: Acorda Surges As Point72 Hikes Stake, Novan Sinks On Failed Study, Illumina-Pac Bio Terminate Merger",2020-01-03 07:55:00-05:00,INCY,negative
664680.0,18 Stocks Moving in Friday's Pre-Market Session,2020-01-03 07:31:00-05:00,INCY,neutral
664681.0,"Cantor Fitzgerald Maintains Neutral on Incyte, Lowers Price Target to $65",2020-01-03 07:24:00-05:00,INCY,negative
664682.0,"JMP Securities Maintains Market Outperform on Incyte, Lowers Price Target to $99",2020-01-03 06:54:00-05:00,INCY,positive
664683.0,"Mizuho Downgrades Incyte to Neutral, Lowers Price Target to $79",2020-01-03 06:40:00-05:00,INCY,negative
664684.0,Incyte Announces Itacitinib Did Not Statistically Improve Overall Response Rate Or Non-Relapse Mortality Compared To Placebo In Phase 3 Study,2020-01-02 16:32:00-05:00,INCY,negative
664685.0,Incyte Option Alert: Jan 17 $92.5 Calls Sweep (2) near the Ask: 987 @ $0.625 vs 1400 OI; Earnings 2/13 Before Open [est] Ref=$85.5602,2020-01-02 11:46:00-05:00,INCY,positive
664686.0,INCY	 Incyte Option Alert: Jan 17 $87.5 Calls Sweep (56) near the Ask: 824 @ $1.796 vs 860 OI; Earnings 2/13 Before Open [est] Ref=$85.55,2020-01-02 11:44:00-05:00,INCY,positive
664687.0,Guggenheim Securities Downgrades Incyte to Neutral,2020-01-02 07:18:00-05:00,INCY,positive
664688.0,"Week Ahead In Biotech: PDUFA Date Ahead For Astra Zeneca, Merck's Lynparza, Pending Clinical Readouts In Focus",2019-12-29 18:38:00-05:00,INCY,neutral
664689.0,10 Biotech M&A Targets Under The Scanner For 2020,2019-12-24 07:30:00-05:00,INCY,neutral
664690.0,A Perspective On Biopharma's Record M&A Run In 2019,2019-12-23 14:57:00-05:00,INCY,neutral
664691.0,"The Daily Biotech Pulse: European Nod For Amgen, miRagen Overhauls Clinical Pipeline, Tonix Snags Patent Win",2019-12-12 07:38:00-05:00,INCY,positive
664692.0,Stocks That Hit 52-Week Highs On Wednesday,2019-12-11 10:49:00-05:00,INCY,neutral
664693.0,"The Daily Biotech Pulse: Correvio Faces FDA Panel Rejection, Iterum's Antibiotic Trial Narrowly Misses Primary Endpoint",2019-12-11 07:21:00-05:00,INCY,negative
664694.0,Stocks That Hit 52-Week Highs On Tuesday,2019-12-10 14:27:00-05:00,INCY,neutral
664695.0,9 Most Overbought Stocks In The S&P 500,2019-12-09 10:35:00-05:00,INCY,neutral
664696.0,"Cramer Gives His Take On Bank Of America, BlackBerry And More",2019-12-09 07:18:00-05:00,INCY,neutral
664697.0,"The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling",2019-12-07 08:35:00-05:00,INCY,positive
664698.0,"The Daily Biotech Pulse: Cassava Gains On Alzheimer's Presentation, Bristol-Myers Hikes Dividend",2019-12-06 07:39:00-05:00,INCY,positive
664699.0,Stocks That Hit 52-Week Highs On Thursday,2019-12-05 10:16:00-05:00,INCY,neutral
664700.0,"The Daily Biotech Pulse: Aurinia Rips Higher On Positive Readout, Sesen Bio On Track For Vicinium BLA Submission",2019-12-05 07:14:00-05:00,INCY,positive
664701.0,"The Daily Biotech Pulse: Astellas To Buy Audentes For $3B, Applied Genetics Chief Medical Officer Quits, Axsome Aces Midstage Trial",2019-12-03 07:59:00-05:00,INCY,neutral
664702.0,Shares of several healthcare stocks are trading lower as US equities dip following escalating US-China tensions over Hong Kong. US Stocks further fell on worse-than-expected manufacturing data.,2019-12-02 11:31:00-05:00,INCY,negative
664703.0,Stocks That Hit 52-Week Highs On Monday,2019-12-02 10:15:00-05:00,INCY,neutral
664704.0,Stocks That Hit 52-Week Highs On Friday,2019-11-29 10:28:00-05:00,INCY,neutral
664705.0,Incyte Announces Acceptance and Priority Review of NDA for Pemigatinib as a Treatment for Patients with Cholangiocarcinoma,2019-11-27 07:31:00-05:00,INCY,positive
664706.0,"The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit's NASH Drug",2019-11-26 08:06:00-05:00,INCY,positive
664707.0,Stocks That Hit 52-Week Highs On Monday,2019-11-25 10:19:00-05:00,INCY,neutral
664708.0,Incyte shares are trading higher. Not seeing any news to justify the price action.,2019-11-25 10:13:00-05:00,INCY,positive
664709.0,"The Daily Biotech Pulse: Patent Win For Cellectis, Hepion Proves Efficacy In Animal Model, Job Cuts At Neon",2019-11-21 07:22:00-05:00,INCY,positive
664710.0,"CVS, Incyte And More 'Fast Money Halftime Report' Picks From Nov. 13",2019-11-13 16:56:00-05:00,INCY,neutral
664711.0,Incyte shares are trading higher after the company reported better-than-expected Q3 EPS and sales results.,2019-10-29 09:01:00-04:00,INCY,positive
664712.0,28 Healthcare Stocks Moving In Tuesday's Pre-Market Session,2019-10-29 08:33:00-04:00,INCY,neutral
664713.0,"The Daily Biotech Pulse: Mirati Tastes Success With KRAS Inhibitor, Roche-Spark Deal Delayed Further, Morphosys Halts Study",2019-10-29 07:32:00-04:00,INCY,positive
664714.0,Incyte Raises FY19 Jakafi Net Product Revenues,2019-10-29 07:11:00-04:00,INCY,neutral
664715.0,"Incyte Q3 Adj. EPS $0.82 Beats $0.65 Estimate, Sales $551.581M Beat $534.88M Estimate",2019-10-29 07:10:00-04:00,INCY,neutral
664716.0,"Earnings Scheduled For October 29, 2019",2019-10-29 04:57:00-04:00,INCY,neutral
664717.0,11 Stocks With The Highest Gross Margins,2019-10-28 17:10:00-04:00,INCY,negative
664718.0,16 Stocks With The Highest Long-Term Sales Growth Rate,2019-10-23 15:26:00-04:00,INCY,positive
664719.0,14 Stocks With The Highest Long-Term Projected Earnings Growth Rates,2019-10-22 10:15:00-04:00,INCY,positive
664720.0,Incyte Reports REACH2 Trial Of Jakai Met Primary Endpoint,2019-10-16 07:01:00-04:00,INCY,neutral
664721.0,Incyte Announces Positive 52-Week Results from Randomized Phase 2 Study of Ruxolitinib Cream in Patients With Vitiligo,2019-10-12 15:49:00-04:00,INCY,positive
664722.0,"Benzinga's Top Upgrades, Downgrades For October 3, 2019",2019-10-03 10:07:00-04:00,INCY,positive
664723.0,"Mizuho Initiates Coverage On Incyte with Buy Rating, Announces $95 Price Target",2019-10-03 06:34:00-04:00,INCY,neutral
664724.0,10 Biggest Price Target Changes For Monday,2019-09-30 09:24:00-04:00,INCY,neutral
664725.0,"JMP Securities Maintains Market Outperform on Incyte, Raises Price Target to $110",2019-09-30 07:32:00-04:00,INCY,positive
664726.0,"The Week Ahead In Biotech (Sept. 29-Oct. 5): Conference Presentations, IPOs Hit Top Gear",2019-09-29 15:01:00-04:00,INCY,positive
664727.0,Incyte Reports Updated Results From Phase 2 Trial Of Pemigatinib In Patients With Previously-Treated Advanced Cholangiocarcinoma,2019-09-27 08:02:00-04:00,INCY,positive
664728.0,"The Daily Biotech Pulse: ESMO Conference Gets Underway, J&J's Darzalex Snags Another Approval, Kaleido Biosciences CFO To Leave",2019-09-27 07:56:00-04:00,INCY,positive
664729.0,"Shares of several healthcare companies are trading lower, potentially on recent Democratic primary polls showing Senator Elizabeth Warren in the lead.",2019-09-26 12:43:00-04:00,INCY,neutral
664730.0,Incyte Announces First Patient Treated In Phase 3 Clinical Trial Program Evaluating Ruxolitinib Cream In Patients With Vitiligo,2019-09-25 07:34:00-04:00,INCY,neutral
664731.0,Shares of many pharma/therapeutics stocks trading lower in sympathy with overall market weakness. Reports China is planning to cut prices for widely-used drugs may also be pressuring the sector today.,2019-09-24 14:01:00-04:00,INCY,negative
664732.0,Incyte shares are trading lower on seemingly no company-specific news.,2019-09-23 11:33:00-04:00,INCY,negative
664733.0,"Incyte to Host September 27, Investor Conference Call From ESMO 2019",2019-09-23 07:33:00-04:00,INCY,neutral
664734.0,The Week Ahead In Biotech: Spotlight On ESMO Conference,2019-09-22 16:22:00-04:00,INCY,neutral
664735.0,Shares of several drug companies are trading higher after Senate Majority Leader McConnell suggested a new Democratic drug price reform proposal would be dead on arrival.,2019-09-20 13:00:00-04:00,INCY,negative
664736.0,Incyte shares are trading higher after on seemingly no company-specific news.,2019-09-16 12:31:00-04:00,INCY,neutral
664737.0,"Incyte shares are trading lower after BMO analysts initiated coverage on the stock with a Market Perform rating, citing 'uncertain' commercial potential for some of the company's potential products.",2019-09-12 12:01:00-04:00,INCY,neutral
664738.0,"Benzinga's Top Upgrades, Downgrades For September 12, 2019",2019-09-12 09:32:00-04:00,INCY,positive
664739.0,"BMO Capital Initiates Coverage On Incyte with Market Perform Rating, Announces $85 Price Target",2019-09-12 06:57:00-04:00,INCY,neutral
664740.0,12 Stocks With The Most Earnings Upside Potential,2019-09-11 07:25:00-04:00,INCY,neutral
664741.0,"UPDATE: JMP Assumes Incyte As Market Outperform, Announces $107 Target As Firm Cites 3 'Remaining milestones in 2019 to drive shareholder value near term':",2019-09-05 13:25:00-04:00,INCY,positive
664742.0,"Benzinga's Top Upgrades, Downgrades For September 5, 2019",2019-09-05 09:38:00-04:00,INCY,positive
664743.0,10 Biggest Price Target Changes For Thursday,2019-09-05 09:12:00-04:00,INCY,neutral
664744.0,"JMP Securities Assumes Incyte at Market Outperform, Announces $107 Price Target; BZ Note: On August 1, 2018 JMP Downgraded Incyte To Market Perform",2019-09-05 08:09:00-04:00,INCY,positive
664745.0,"Oppenheimer Upgrades Incyte to Outperform, Raises Price Target to $100",2019-09-05 06:59:00-04:00,INCY,neutral
664746.0,"Morgan Stanley Assumes Incyte at Equal-Weight, Raises $87 Price Target",2019-09-05 06:48:00-04:00,INCY,neutral
664747.0,"Shares of several healthcare companies are trading lower after the Johnson & Johnson opioid crisis ruling. It is seen as an ominous sign for things to come for the whole sector as there are still 2,000 more lawsuits awaiting.",2019-08-27 12:49:00-04:00,INCY,negative
664748.0,"Eli Lilly Reports Baricitinib Met Primary Endpoint In Breeze-AD7, Third Pivotal Phase 3 Trial In Breeze-AD Program To Be Completed In 2019",2019-08-23 14:58:00-04:00,INCY,neutral
664749.0,Shares of several healthcare companies are trading higher as optimism increased for a resolution to the US-China trade war.,2019-08-19 12:31:00-04:00,INCY,positive
664750.0,"Shares of healthcare companies are trading higher as US markets rebound from recent weakness following a yield curve inversion, which caused recession fears. Trump also recently announced the US would delay China tariffs, renewing hopes of a trade deal.",2019-08-16 13:27:00-04:00,INCY,negative
664751.0,﻿Shares of several healthcare companies are trading higher with the overall market after the U.S. announced it is excluding and delaying the additional 10% tariff on certain products.,2019-08-13 11:53:00-04:00,INCY,positive
664752.0,"Nomura Maintains Buy on Incyte, Raises Price Target to $111",2019-07-31 08:53:00-04:00,INCY,neutral
664753.0,"Morgan Stanley Maintains Equal-Weight on Incyte, Raises Price Target to $82",2019-07-31 07:57:00-04:00,INCY,neutral
664754.0,33 Healthcare Stocks Moving In Today's Pre-Market Session,2019-07-30 09:16:00-04:00,INCY,neutral
664755.0,"Incyte Narrows, Raises Lower End Of FY19 Jakafi Sales Guidance To $1.61B-$1.65B",2019-07-30 07:09:00-04:00,INCY,negative
664756.0,"Incyte Q2 EPS $0.48, Inline, Sales $529.93M Beat $496.4M Estimate",2019-07-30 07:05:00-04:00,INCY,neutral
664757.0,"The Daily Biotech Pulse: European Cheer For Merck, Legal Victory For Coherus, Medpace Picks Up On Earnings",2019-07-30 07:00:00-04:00,INCY,positive
664758.0,"The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate",2019-07-27 14:32:00-04:00,INCY,negative
664759.0,Shares of several drug manufacturing companies are trading lower. The Trump Administration earlier rolled back a proposal to eliminate rebates from government drug plans and commented on continued efforts to lower drug prices.,2019-07-11 10:36:00-04:00,INCY,negative
664760.0,"Shares of several healthcare companies are trading lower after Trump on Friday said he was preparing an executive order declaring a 'favored nations clause' for drug prices, lowering the price that consumers will pay prescription drugs.",2019-07-08 12:55:00-04:00,INCY,positive
664761.0,Incyte And Zai Lab Announce Collaboration And License Agreement For INCMGA0012 In Greater China; Zai Lab To Pay Incyte $17.5M Up Front And Up To $60M In Milestones,2019-07-02 07:31:00-04:00,INCY,positive
664762.0,36 Stocks Moving In Wednesday's Pre-Market Session,2019-06-19 08:17:00-04:00,INCY,neutral
664763.0,Inycte On Saturday Announced Positive Results From Phase 2 Study Of Ruxolitinib Cream In Patients With Vitiligo,2019-06-17 10:11:00-04:00,INCY,positive
664764.0,Incyte shares are trading higher after the company announced positive results from a Phase 2 study of Ruxolitinib cream in patients with Vitiligo.,2019-06-17 09:43:00-04:00,INCY,positive
664765.0,"The Daily Biotech Pulse:  Hematology And Rheumatology Conference Presentations Take The Spotlight, Eton In-Licenses Epilepsy Drug NDA",2019-06-14 08:47:00-04:00,INCY,neutral
664766.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts",2019-06-08 16:09:00-04:00,INCY,neutral
664767.0,Shares of several healthcare companies are trading higher with the overall US market. Recent comments out of China and Mexico has renewed trade optimism and lifted economic outlook.,2019-06-04 13:07:00-04:00,INCY,positive
664768.0,Incyte Reports First Patient Treated In Phase 3 Trial Of Pemigatinib As First-Line Therapy for Cholangiocarcinoma,2019-06-04 07:30:00-04:00,INCY,neutral
664769.0,The Week Ahead In Biotech: ASCO Presentations Pick Up The Pace,2019-06-01 11:37:00-04:00,INCY,neutral
664770.0,The Week Ahead In Biotech: ASCO Presentations In The Spotlight,2019-05-26 17:03:00-04:00,INCY,neutral
664771.0,FDA Approves Incyte's Jakafi For The Treatment Of Patients With Acute Graft-Versus-Host Disease,2019-05-24 13:44:00-04:00,INCY,positive
664772.0,"The Daily Biotech Pulse: FDA Nod For Novocure, Dynavax Restructures, Therapix Receives Nasdaq Notice",2019-05-24 07:44:00-04:00,INCY,neutral
664773.0,"Benzinga's Top Upgrades, Downgrades For May 21, 2019",2019-05-21 09:16:00-04:00,INCY,positive
664774.0,"Credit Suisse Initiates Coverage On Incyte Corporation - Common Stock with Neutral Rating, Announces $75 Price Target",2019-05-21 07:15:00-04:00,INCY,positive
664775.0,Incyte Reports Data From Co.'s Inflammation and Autoimmunity Portfolio to be Featured at the 24th World Congress of Dermatology,2019-05-20 07:31:00-04:00,INCY,neutral
664776.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs",2019-05-18 09:50:00-04:00,INCY,neutral
664777.0,Incyte Announces That Multiple Abstracts Highlighting Data From Its Oncology Portfolio Will Be Presented At The Upcoming 2019 American Society Of Clinical Oncology Annual Meeting From May 31-June 4 In Chicago Illinois,2019-05-16 12:01:00-04:00,INCY,neutral
664778.0,"Shares of several healthcare companies are trading lower amid continued trade dispute between the US and China. Also, the United States filed a lawsuit against drug manufacturers alleging price fixing.",2019-05-13 10:35:00-04:00,INCY,negative
664779.0,Shares of several healthcare companies are trading lower in sympathy with the overall market. The S&P 500 is trading lower 1%,2019-05-10 13:09:00-04:00,INCY,positive
664780.0,10 Biggest Price Target Changes For Friday,2019-05-03 10:43:00-04:00,INCY,neutral
664781.0,"Benzinga's Top Upgrades, Downgrades For May 3, 2019",2019-05-03 08:53:00-04:00,INCY,positive
664782.0,"Barclays Downgrades Incyte Corporation - Common Stock to Equal-Weight, Lowers Price Target to $82",2019-05-03 06:48:00-04:00,INCY,negative
664783.0,Attention Biotech Investors: Mark Your Calendar For These May PDUFA Dates,2019-04-30 13:00:00-04:00,INCY,neutral
664784.0,Incyte shares are trading higher after the company reported better-than-expected Q1 EPS and sales.,2019-04-30 10:18:00-04:00,INCY,positive
664785.0,"Incyte Q1 EPS $0.62 Beats $0.41 Estimate, Sales $497.857M Beat $486.2M Estimate",2019-04-30 07:24:00-04:00,INCY,neutral
664786.0,"Shares of several healthcare-related stocks are trading higher in a potential rebound from last week's selloff. In an upgrade of HCA Healthcare, Raymond James analysts noted the selloff was 'based on legislation that has almost no chance of passing'.",2019-04-23 14:30:00-04:00,INCY,positive
664787.0,Shares of several drug companies are trading lower amid continued efforts from Washington to curb prescription drug prices. The overall healthcare sector has seen weakness recently due to uncertainty over the future of healthcare policy.,2019-04-18 10:51:00-04:00,INCY,negative
664788.0,Shares of several drug companies are trading lower amid continued efforts from Washington to curb prescription drug prices. The overall healthcare sector has seen weakness recently due to uncertainty over the future of healthcare policy.,2019-04-17 10:31:00-04:00,INCY,negative
664789.0,"Benzinga's Top Upgrades, Downgrades For April 11, 2019",2019-04-11 09:09:00-04:00,INCY,positive
664790.0,"Stifel Nicolaus Initiates Coverage On Incyte with Hold Rating, Announces $82 Price Target",2019-04-11 07:21:00-04:00,INCY,neutral
664791.0,Concert Pharmaceuticals Loses IPR Patent Trial As PTAB Rules Incyte Proved That Concert '149 Patent Claims Are Unpatentable,2019-04-08 14:06:00-04:00,INCY,negative
664792.0,RBC Capital Downgrades Incyte to Sector Perform,2019-04-03 07:12:00-04:00,INCY,neutral
664793.0,BriaCell Announces Clinical Trial Collaboration Agreement With Incyte,2019-04-02 15:00:00-04:00,INCY,positive
664794.0,Merus and Incyte Present MCLA-145 Program Preclinical Data at the AACR Annual Meeting 2019,2019-04-01 07:07:00-04:00,INCY,neutral
664795.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs",2019-03-30 09:32:00-04:00,INCY,neutral
664796.0,"Argus Maintains Buy on Incyte, Raises Price Target to $98",2019-02-25 09:32:00-05:00,INCY,neutral
664797.0,Incyte Corp Files For ~34.13M Share Common Stock Offering,2019-02-14 16:40:00-05:00,INCY,positive
664798.0,"Incyte Q4 Adj. EPS $0.40 Misses $0.47 Estimate, Sales $528.402M Beat $485.8M Estimate",2019-02-14 07:49:00-05:00,INCY,negative
664799.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials",2019-02-10 17:37:00-05:00,INCY,neutral
664800.0,"Incyte Reports FDA Has Extended Review Period For Jakafi in Acute Graft-Versus-Host Disease; New PDUFA Date Is May 24, 2019",2019-02-07 07:20:00-05:00,INCY,neutral
664801.0,Eli Lilly Announces Two Phase 3 Trials of Baricitinib Met Their Primary Endpoints,2019-02-04 06:48:00-05:00,INCY,neutral
664802.0,Attention Biotech Investors: Mark Your Calendar For These February PDUFA Dates,2019-02-01 13:30:00-05:00,INCY,neutral
664803.0,10 Biggest Price Target Changes For Thursday,2019-01-24 09:51:00-05:00,INCY,neutral
664804.0,UPDATE:  William Blair Upgrades Incyte As Firm Sees 'see Incyte executing on both commercial and R&D fronts to balance driving near-term profitability growth and realizing long-term appreciation from a resurgent pipeline',2019-01-24 09:33:00-05:00,INCY,positive
664805.0,"Benzinga's Top Upgrades, Downgrades For January 24, 2019",2019-01-24 09:02:00-05:00,INCY,positive
664806.0,"William Blair Upgrades Incyte to Outperform, Raises Price Target to $100",2019-01-24 06:38:00-05:00,INCY,neutral
664807.0,Gabelli & Co. Upgrades Incyte to Buy,2019-01-24 06:37:00-05:00,INCY,neutral
664808.0,Incyte Announces First Patient Treated In Phase 3 Clinical Trial Of Itacitinib For Chronic Graft-Versus-Host Disease,2019-01-22 07:31:00-05:00,INCY,neutral
664809.0,10 Biggest Price Target Changes For Wednesday,2019-01-16 09:46:00-05:00,INCY,neutral
664810.0,"UBS Downgrades Incyte to Neutral, Raises Price Target to $82",2019-01-16 07:33:00-05:00,INCY,neutral
664811.0,Incyte shares are trading higher after Goldman Sachs added the stock to its Conviction List.,2019-01-15 10:56:00-05:00,INCY,positive
664812.0,"Raymond James Maintains Strong Buy On Incyte As Firm Sees Many Catalysts In 2019 Including the 'potential approval of rux in SR acute GVHD', 'Phase III results from the REACH2 and REACH3 studies in SR-aGVHD and SR chronic GVHD', Among Others",2019-01-09 08:49:00-05:00,INCY,positive
664813.0,58 Biggest Movers From Yesterday,2019-01-04 05:35:00-05:00,INCY,neutral
664814.0,44 Stocks Moving In Thursday's Mid-Day Session,2019-01-03 12:27:00-05:00,INCY,neutral
664815.0,Incyte shares are trading higher after Guggenheim upgraded the stock from Neutral to Buy.,2019-01-03 09:45:00-05:00,INCY,positive
664816.0,Guggenheim Upgrades Incyte to Buy,2019-01-03 08:31:00-05:00,INCY,neutral
664817.0,Incyte Names Christiana Stamoulis CFO,2019-01-03 07:00:00-05:00,INCY,neutral
664818.0,Incyte Reports First Patient Treated In Phase 3 Trial For Ruxolitinib Cream In Atopic Dermatitis,2018-12-20 16:31:00-05:00,INCY,neutral
664819.0,"Innovent, Incyte Announce Strategic Collaboration, Licensing Agreement for Three Clinical-stage Product Candidates in China; Incyte to Receive $40M Upfront; Up to $331M in Regulatory and Commercial Milestones",2018-12-16 20:22:00-05:00,INCY,positive
664820.0,Eli Lilly Reports Fast Track Designation To Baricitinib Development Program For Treatment Of Systemic Lupus Erythematosus,2018-12-13 06:46:00-05:00,INCY,neutral
664821.0,5 Biotech Companies To Keep On Your M&A Watchlist For 2019,2018-12-10 12:32:00-05:00,INCY,neutral
664822.0,Incyte To Present Updated Results From Phase 2 REACH1 Study Evaluating Jakafi In Combo With Corticosteroids As Treatment For Patients With Acute Graft-Versus-Host Disease At ASH,2018-12-03 10:14:00-05:00,INCY,neutral
664823.0,"The Week Ahead In Biotech: ASH Presentations Pick Up Pace, PDUFA Dates, Clinical Trials And IPOs",2018-12-02 17:51:00-05:00,INCY,neutral
664824.0,"Stocks That Made New 52-Week Lows So Far Today Include: Weyerhaeuser, Symantec, AIG, Moody's, LyndonBassell, Williams Companies, Xylem, IBM, Northrop Grumman, Constellation Brands, Cognizant Tech, Raytheon, Incyte, and Eaton",2018-10-30 12:46:00-04:00,INCY,negative
664825.0,Incyte shares are trading down 5.5% after the company missed Q3 EPS and revenue estimates.,2018-10-30 12:18:00-04:00,INCY,neutral
664826.0,"The Daily Biotech Pulse: Pfizer And Allergan Earnings, CFO Departures At Acadia And Assertio",2018-10-30 08:00:00-04:00,INCY,neutral
664827.0,"Incyte Corporation Q3 EPS $0.38 Misses $0.40 Estimate, Sales $429.683M Miss $450.38M Estimate",2018-10-30 07:29:00-04:00,INCY,negative
664828.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results, Earnings And IPOs",2018-10-27 10:23:00-04:00,INCY,neutral
664829.0,Incyte Corporation Reports FDA Granted Priority Review For Ruxolitinib For Patients With Acute Graft-Versus-Host Disease,2018-10-25 08:01:00-04:00,INCY,positive
664830.0,11 Stocks That Moved From ESMO 2018,2018-10-22 13:39:00-04:00,INCY,neutral
664831.0,"The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results, Large-Cap Pharma Earnings And IPOs",2018-10-21 17:15:00-04:00,INCY,neutral
664832.0,"Incyte Announces Positive Interim Data from Phase 2 Trial of Pemigatinib, Its Selective FGFR Inhibitor, in Patients with Cholangiocarcinoma, Which Support Planned submission of NDA in U.S. in 2019 at ESMO 2018",2018-10-21 08:14:00-04:00,INCY,positive
664833.0,"Incyte Reports Phase 2 GEOMETRY Mono-1 Trial Of Investigational Medicine Capmatinib Showed 'overall response rate of 72%, 39.1%, respectively, in treatment-naive and previously treated patients with advanced MET exon-14 skipping mutated NSCLC'",2018-10-19 10:13:00-04:00,INCY,positive
664834.0,"Cantor Fitzgerald Initiates Coverage On Incyte with Neutral Rating, Announces $73 Price Target",2018-10-01 08:18:00-04:00,INCY,neutral
664835.0,"Leerink Swann Initiates Coverage On Incyte with Market Perform Rating, Announces $78 Price Target",2018-09-25 08:52:00-04:00,INCY,neutral
664836.0,"XOMA Reports Purchase Of Royalty Interest Position From Agenus On 7 Assets Being Developed By Merck, Incyte For $15M",2018-09-21 07:00:00-04:00,INCY,positive
664837.0,"Agenus 8-K Shows License, Development, Commercialization Deal With Incyte; Co. Remains Eligible To Receive Up To $505M In Potential Milestones, Plus Royalties On Future Sales Ranging From 6-15%",2018-09-21 06:37:00-04:00,INCY,neutral
664838.0,"Incyte Reports Data From Phase 2b Trial Of Ruxolitinib Cream In Patients With Atopic Dermatitis: Met Primary, Key Secondary Endpoints",2018-09-13 07:30:00-04:00,INCY,neutral
664839.0,Aerie Pharma Names Former Incyte CFO David Gryska to its Board,2018-09-12 16:03:00-04:00,INCY,neutral
664840.0,"The Daily Biotech Pulse: Advaxis Posts Narrower Loss, Endocyte Announces $175M Offering, Leadership Transition At Insulet",2018-09-11 08:25:00-04:00,INCY,negative
664841.0,"Incyte And Foundation Medicine Announce Agreement To Develop Companion Diagnostic For Pemigatinib (INCB54828), A Selective FGFR Inhibitor, In Cholangiocarcinoma Patients",2018-09-11 07:31:00-04:00,INCY,positive
664842.0,"The Week Ahead In Biotech: Conferences, Clinical Trial Results, Earnings And IPOs",2018-09-09 16:46:00-04:00,INCY,neutral
664843.0,5 Stocks To Have On Your Radar Next Week,2018-09-07 13:11:00-04:00,INCY,neutral
664844.0,Incyte Announces CFO David Gryska To Retire At End Of 2018,2018-09-06 16:31:00-04:00,INCY,neutral
664845.0,"Incyte Has Quietly Risen 13 Percent In The Last Two Weeks, And That Uptrend Looks Like It Will Continue",2018-08-21 15:40:00-04:00,INCY,positive
664846.0,"Benzinga's Top Upgrades, Downgrades For August 15, 2018",2018-08-15 09:10:00-04:00,INCY,positive
664847.0,RBC Capital Upgrades Incyte to Outperform,2018-08-15 08:06:00-04:00,INCY,neutral
664848.0,"Benzinga's Top Upgrades, Downgrades For August 1, 2018",2018-08-01 09:08:00-04:00,INCY,positive
664849.0,JMP Securities Downgrades Incyte to Market Perform,2018-08-01 07:22:00-04:00,INCY,positive
664850.0,"Incyte Q2 Adj. EPS $0.26 Misses $0.35 Estimate, Sales $521.516M Beat $473.78M Estimate",2018-07-31 07:11:00-04:00,INCY,negative
664851.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs",2018-07-28 14:04:00-04:00,INCY,neutral
664852.0,Eli Lilly And Incyte Late Thursday Announced Study Results Showing Benefit Of Baricitinib 4 mg For Treatment Of Systemic Lupus Erythematosus (SLE) Were Published In The Lancet,2018-07-20 09:01:00-04:00,INCY,positive
664853.0,"Oppenheimer Maintains Perform on Incyte, Raises Price Target to $70",2018-07-18 08:16:00-04:00,INCY,neutral
664854.0,"Benzinga's Bulls & Bears Of The Week: AT&T, Facebook, Intel, Netflix, Twitter And More",2018-07-15 15:42:00-04:00,INCY,neutral
664855.0,"Incyte Has Limited Catalysts In Next 6 Months; But 2019 Could Be Pivotal, Morgan Stanley Says In Downgrade",2018-07-13 10:16:00-04:00,INCY,negative
664856.0,"Benzinga's Top Upgrades, Downgrades For July 13, 2018",2018-07-13 09:05:00-04:00,INCY,positive
664857.0,"The Market In 5 Minutes: AT&T-Time Warner Appeal, Johnson & Johnson Lawsuit, Theresa May And More",2018-07-13 08:19:00-04:00,INCY,negative
664858.0,Morgan Stanley Downgrades Incyte to Equal-Weight,2018-07-13 07:11:00-04:00,INCY,neutral
664859.0,A Look At Biotech In 2018 And The Biggest Catalysts Coming Up In The Second Half Of The Year,2018-07-05 12:25:00-04:00,INCY,neutral
664860.0,"Benzinga's Bulls & Bears Of The Week: Amazon, GE, Intel, T-Mobile And More",2018-07-01 17:28:00-04:00,INCY,positive
664861.0,A 2018 Midyear Update: The 10 Worst-Performing S&P 500 Stocks,2018-07-01 16:56:00-04:00,INCY,neutral
664862.0,54 Biggest Movers From Yesterday,2018-06-27 04:51:00-04:00,INCY,neutral
664863.0,Incyte Shares Down 7.1% After RBC Downgraded Stock From Outperform To Sector Perform And Lowered Price Target $76 To $74,2018-06-26 13:07:00-04:00,INCY,positive
664864.0,40 Stocks Moving In Tuesday's Mid-Day Session,2018-06-26 12:32:00-04:00,INCY,neutral
664865.0,Incyte Downgraded As RBC Analyst Awaits More Revenue Visibility,2018-06-26 12:18:00-04:00,INCY,positive
664866.0,"Benzinga's Top Upgrades, Downgrades For June 26, 2018",2018-06-26 09:06:00-04:00,INCY,positive
664867.0,"RBC Capital Downgrades Incyte to Sector Perform, Lowers Price Target to $74",2018-06-26 08:19:00-04:00,INCY,negative
664868.0,Analyst IPO Quiet Period Expires Today for Incyte,2018-06-21 07:10:00-04:00,INCY,neutral
664869.0,Incyte Announces REACH1 Pivotal Trial Meets Primary Endpoint Of Overall Response Rate For Ruxolitinib (Jakafi) In Steroid-Refractory Acute Graft-Versus-Host Disease,2018-06-21 07:07:00-04:00,INCY,neutral
664870.0,"The Week Ahead: Pharma IPOs Galore, Blackberry Earnings And More",2018-06-18 13:06:00-04:00,INCY,neutral
664871.0,Evercore ISI Group Upgrades Incyte To Outperform,2018-06-11 10:16:00-04:00,INCY,neutral
664872.0,Hearing Josh Schimmer Of Evercore ISI Upgraded Incyte Corp To Outperform,2018-06-11 10:00:00-04:00,INCY,neutral
664873.0,"Eli Lilly CEO Calls For Uniform Prices, Better Use Of Technology In Health Care",2018-06-07 16:24:00-04:00,INCY,positive
664874.0,Watching Shares of Incyte as Traders In Chatrooms Pass Unconfirmed Chatter They've Received a Takeover Approach,2018-06-07 11:09:00-04:00,INCY,positive
664875.0,The Week Ahead In Biotech: ASCO Presentations Dominate The Headlines,2018-06-03 19:27:00-04:00,INCY,negative
664876.0,Eli Lilly Press Release Confirms Earlier News Of FDA Approval For Olumiant,2018-06-01 12:05:00-04:00,INCY,positive
664877.0,Benzinga's Daily Biotech Pulse: Organovo Falls On Earnings; Celgene Gets New CFO,2018-06-01 08:16:00-04:00,INCY,neutral
664878.0,"Benzinga's Top Upgrades, Downgrades For May 31, 2018",2018-05-31 09:23:00-04:00,INCY,positive
664879.0,"PiperJaffray Assumes Incyte at Overweight, Announces Price Target $85",2018-05-31 08:11:00-04:00,INCY,negative
664880.0,The Week Ahead In Biotech: ASCO Presentations In The Spotlight,2018-05-26 11:07:00-04:00,INCY,neutral
664881.0,"Jim Cramer Gives His Opinion On Blue Apron, Teva And More",2018-05-24 07:33:00-04:00,INCY,neutral
664882.0,"Benzinga's Daily Biotech Pulse: SIGA Rallies On FDA Panel Backing, Rigel And Gilead React To Earnings",2018-05-02 07:41:00-04:00,INCY,neutral
664883.0,"Incyte Pharma Reports Q1 Adj. EPS $(0.01) Misses $0.01 Est., Sales $382.28M Misses $390.05M Est.",2018-05-01 07:08:00-04:00,INCY,negative
664884.0,"Syros Takes The Road Less Traveled In Gene Control, Awaits Windfall From Diverse Indications",2018-04-25 14:57:00-04:00,INCY,positive
664885.0,38 Biggest Movers From Yesterday,2018-04-25 04:12:00-04:00,INCY,neutral
664886.0,32 Stocks Moving In Tuesday's Mid-Day Session,2018-04-24 12:26:00-04:00,INCY,neutral
664887.0,28 Stocks Moving In Tuesday's Pre-Market Session,2018-04-24 08:01:00-04:00,INCY,neutral
664888.0,"JP Morgan Maintains Overweight on Incyte, Lowers Price Target to $88.00",2018-04-24 07:49:00-04:00,INCY,negative
664889.0,"Lilly, Incyte Announce FDA Advisory Committee Recommends Approval of Baricitinib 2mg, Not 4mg, for Treatment of Moderately-to-Severely Active RA",2018-04-24 03:56:00-04:00,INCY,positive
664890.0,"The Week Ahead: Sohn Conference, FANG Earnings, DocuSign IPO",2018-04-23 10:44:00-04:00,INCY,neutral
664891.0,REMINDER: Eli Lilly and Incyte Have FDA AdCom Meeting For Baricitinib Today,2018-04-23 06:59:00-04:00,INCY,neutral
664892.0,"The Week Ahead In Biotech: PDUFA Dates, IPOs And More",2018-04-20 14:00:00-04:00,INCY,neutral
664893.0,"FDA Staff Review Of Eli Lilly's Rheumatoid Arthritis Treatment Says Supportive Of 2mg Dose, But Not 4mg Dose",2018-04-19 07:58:00-04:00,INCY,positive
664894.0,UBS Upgrades Incyte to Buy,2018-04-12 08:51:00-04:00,INCY,neutral
664895.0,"Biotech Stock Roundup: Spectrum Up, Incyte Down, AveXis To Merge With Novartis And More",2018-04-11 14:31:00-04:00,INCY,neutral
664896.0,"Morgan Stanley Maintains Overweight on Incyte, Lowers Price Target to $76.00",2018-04-10 10:34:00-04:00,INCY,negative
664897.0,Incyte Option Alert: Jun 15 $80 Calls at the Ask: 1750 @ $2.05 vs 1700 OI; Earnings 5/3 Before Open [est] Ref=$65.03,2018-04-09 15:37:00-04:00,INCY,positive
664898.0,"NewLink Genetics' Potential Catalysts Not Enough To Justify A Bullish Stance, Baird Says In Downgrade",2018-04-09 14:24:00-04:00,INCY,neutral
664899.0,Cantor Fitzgerald Double Downgrades NewLink Genetics After Incyte's Disappointing Trial,2018-04-09 10:29:00-04:00,INCY,negative
664900.0,8 Biggest Price Target Changes For Monday,2018-04-09 09:52:00-04:00,INCY,neutral
664901.0,"JP Morgan Maintains Overweight on Incyte, Lowers Price Target to $96.00",2018-04-09 08:32:00-04:00,INCY,negative
664902.0,"Credit Suisse Maintains Outperform on Incyte, Lowers Price Target to $78.00",2018-04-09 08:07:00-04:00,INCY,positive
664903.0,30 Biggest Movers From Friday,2018-04-09 04:23:00-04:00,INCY,neutral
664904.0,"Benzinga's Top Analyst Calls From April 6, 2018",2018-04-06 14:39:00-04:00,INCY,positive
664905.0,Mid-Afternoon Market Update: Crude Oil Down 2%; PriceSmart Shares Spike Higher,2018-04-06 14:33:00-04:00,INCY,negative
664906.0,"Incyte Shares Down ~20% After Failure of ECHO-301/KEYNOTE-252 Combo Trial, Downgrades From Guggenheim and William Blair",2018-04-06 14:28:00-04:00,INCY,negative
664907.0,"Mizuho Out Positive On Nektar Therapeutics Says Incyte's epacadostat Phase 3 Failure Is A Positive For The Company, Believes This News Raises The Possibility Of A Takeout By BMS In The Coming Months",2018-04-06 13:07:00-04:00,INCY,positive
664908.0,24 Stocks Moving In Friday's Mid-Day Session,2018-04-06 12:26:00-04:00,INCY,neutral
664909.0,Mid-Day Market Update: Dow Falls 350 Points; Incyte Shares Plunge,2018-04-06 12:05:00-04:00,INCY,positive
664910.0,Incyte Option Alert: Apr 20 $65 Puts at the Ask: 1508 @ $1.95 vs 261 OI; Earnings 5/3 Before Open [est] Ref=$68.82,2018-04-06 10:46:00-04:00,INCY,positive
664911.0,Mid-Morning Market Update: Markets Open Lower; Greenbrier Beats Q2 Expectations,2018-04-06 10:17:00-04:00,INCY,negative
664912.0,William Blair Downgrades Incyte to Market Perform,2018-04-06 09:39:00-04:00,INCY,neutral
664913.0,Guggenheim Downgrades Incyte to Neutral,2018-04-06 09:33:00-04:00,INCY,neutral
664914.0,'$NKTR is the new $INCY. Anyone worried about that now?' -Adam Feuerstein Tweet,2018-04-06 09:00:00-04:00,INCY,negative
664915.0,Incyte Falls 20% After Cancer Drug Fails Phase 3 Trial,2018-04-06 08:50:00-04:00,INCY,negative
664916.0,UPDATE: Incyte Shares Down 20.5% After its Phase 3 ECGI-301/KEYNOT-252 Study With Merck Did Not Meet the Primary Endpoint,2018-04-06 08:01:00-04:00,INCY,positive
664917.0,"Incyte Shares Resume Trade, Now Down ~$20 At $65.10",2018-04-06 08:00:00-04:00,INCY,positive
664918.0,'The first real test of the cancer immunotherapy combination thesis fails. $INCY $MRK' -Adam Feuerstein Tweet,2018-04-06 07:31:00-04:00,INCY,negative
664919.0,Incyte and Merck Says Phase 3 ECHO-301/KEYNOTE-252 Study Did Not Meet The Primary Endpoint Of Improving Progression-Free Survival,2018-04-06 07:31:00-04:00,INCY,positive
664920.0,"Incyte Halted, News Pending",2018-04-06 07:26:00-04:00,INCY,neutral
664921.0,"Barclays Maintains Overweight on Incyte, Lowers Price Target to $135.00",2018-04-05 13:47:00-04:00,INCY,negative
664922.0,"Stocks That Made New 52-Wk Lows Today Include: Incyte, Merck, Mallinckrodt, Celgene, Cerner, Willams Cos., AMD, Albemarle, Kinder Morgan, Western Union, Walgreens, Kraft Heinz, Nielsen, and Alliance Data Systems",2018-04-03 12:15:00-04:00,INCY,positive
664923.0,Attention Biotech Investors: Mark Your Calendar For These April PDUFA Dates,2018-04-03 08:14:00-04:00,INCY,neutral
664924.0,Hearing Dealreporter Said Novartis Is Weighing A Bid For Incyte,2018-03-28 09:36:00-04:00,INCY,neutral
664925.0,"RBC Capital Global Healthcare Conference Begins Today, Presenters Include: Chemed, Revance, Eagle Pharma, Enanta, Gilead, TransEnterix, Immunogen, and Incyte",2018-02-21 07:14:00-05:00,INCY,neutral
664926.0,"Incyte Reports Q4 EPS $(0.71) vs $0.05 In Same Qtr. Last Year, Sales $444.156M vs $426M Est.",2018-02-15 07:06:00-05:00,INCY,neutral
664927.0,"Earnings Scheduled For February 15, 2018",2018-02-15 04:12:00-05:00,INCY,neutral
664928.0,"Adam Feuerstein Tweets: So… if $INCY epacadostat ECHO-301 study fails but they declare victory in a subset of melanoma patients, everyone is going to be happy? 

Does anything matter anymore?",2018-02-05 08:42:00-05:00,INCY,positive
664929.0,"Cara Therapeutics Shares Up 19.24% As Co. Mentioned In Earlier Opinion Piece As Potential M&A Target; Other Mentions Include: BMRN -0.66%, BLUE +3.87%, ACAD -0.3%, INCY +0.4%",2018-01-24 13:40:00-05:00,INCY,positive
664930.0,Incyte Corporation Recommends Shareholders Reject TRC Capital Corporation's Mini-Tender Offer To Buy 1.5M Shares At $88.88,2018-01-23 08:01:00-05:00,INCY,positive
664931.0,Concert Pharma Drops On Patent Litigation Setback; Mizuho Downgrades,2018-01-12 13:48:00-05:00,INCY,negative
664932.0,"UPDATE: Syros Pharma To Receive $10M Upfront Payment From Incyte And $10M Equity Investment At Premium To Current Market Price, Could Receive Up To $47M In Target Validation & Other Fees, And Another $115M In Milestone Payments",2018-01-08 12:28:00-05:00,INCY,neutral
664933.0,"JP Morgan Healthcare Conference Begins Today, Presenters Include: Gilead, Illumina, Seattle Genetics, Biogen, Incyte, Baxter, Regeneron, Walgreens, Alnylam, Edwards Lifesciences, Molina, Alexion, Celgene, Pfizer, Neurocrine Biosciences, and Jazz Pharma",2018-01-08 09:00:00-05:00,INCY,positive
664934.0,"Incyte, Syros Pharma Report Global Target Discovery, Validation Collab Focused On Myeloproliferative Neoplasms",2018-01-08 08:48:00-05:00,INCY,positive
664935.0,Jim Cramer Advises His Viewers On Incyte And American Outdoor Brands,2018-01-08 07:17:00-05:00,INCY,neutral
664936.0,35 Biggest Movers From Yesterday,2018-01-03 05:03:00-05:00,INCY,neutral
664937.0,28 Stocks Moving In Tuesday's Mid-Day Session,2018-01-02 13:09:00-05:00,INCY,neutral
664938.0,"OncoSec Medical Shares Up 12%; Seeing Social Media Mention This May Be In Sympathy With Fellow Immuno-oncology Play Incyte, Upgraded Earlier At RBC",2018-01-02 12:09:00-05:00,INCY,positive
664939.0,"Benzinga's Top Upgrades, Downgrades For January 2, 2018",2018-01-02 09:29:00-05:00,INCY,positive
664940.0,"The Market In 5 Minutes: Oil's Strong Open, Cohen's Comeback, And A Look Back At 2017's Best And Worst Stocks",2018-01-02 09:00:00-05:00,INCY,positive
664941.0,RBC Capital Upgrades Incyte to Outperform,2018-01-02 06:28:00-05:00,INCY,neutral
664942.0,"Deutsche Bank Initiates Coverage On Incyte with Hold Rating, Announces $106.00 Price Target",2017-12-13 08:39:00-05:00,INCY,neutral
664943.0,3 Stocks In Focus As Biotech M&A Hopes For 2018 Rise,2017-12-11 12:52:00-05:00,INCY,positive
664944.0,Incyte Shares Down 1.64% Premarket; Sunday Co. Reported 4-Year Phase 3 Data From ASH Showing Durability Of Response For Jakafi,2017-12-11 09:16:00-05:00,INCY,positive
664945.0,Incyte Reports Initiation Of Pivotal Trial Of Jakafi For Treatment Of Essential Thrombocythemia,2017-11-15 07:30:00-05:00,INCY,neutral
664946.0,"Lightning Round: Jim Cramer Gives His Opinion On Incyte, Apache And More",2017-11-08 07:47:00-05:00,INCY,neutral
664947.0,"Secondary Offering Lockup Expirations Today For Zealand Pharma, MyoKardia, Consolidated Edison, and Incyte",2017-11-07 09:10:00-05:00,INCY,neutral
664948.0,"The Week Ahead: Earnings Season Continues, Several IPOs, Notable Conferences On The Docket",2017-11-06 10:48:00-05:00,INCY,neutral
664949.0,Here's What Was Intriguing About Incyte's Q3 Report,2017-11-01 15:36:00-04:00,INCY,neutral
664950.0,"Incyte Reports More Than 30 Abstracts Including Data From Programs For Jakafi, JAK1, PI3Kδ,PIM, BRD To Be Presented At ASH",2017-11-01 11:15:00-04:00,INCY,neutral
664951.0,"BMO Raises Price Target On Incyte To New Street High Of $166, As Firm Says They've Raised There Jakafi Estimates In Line With Q3 Run Rate",2017-10-31 15:22:00-04:00,INCY,neutral
664952.0,Incyte Raises Jakafi Net Product Revenue FY17 Guidance From $1.09-$1.12B To $1.125-$1.135B,2017-10-31 07:13:00-04:00,INCY,neutral
664953.0,"Incyte Reports Q3 EPS $0.17 vs $0.07 Est., Sales $381.53M vs $360.24M Est.",2017-10-31 07:12:00-04:00,INCY,neutral
664954.0,"Incyte, AstraZeneca Announce Clinical Trial Collaboration in Early Lung Cancer",2017-10-31 03:43:00-04:00,INCY,negative
664955.0,Incyte and MacroGenics Announce Collaboration and Licensing Agreement for Anti-PD-1 Monoclonal Antibody MGA012,2017-10-25 06:52:00-04:00,INCY,positive
664956.0,Incyte Shares Up 2.9% After-Hours On No Apparent News,2017-10-20 17:00:00-04:00,INCY,neutral
664957.0,Concert Pharma Reports PTAB Has Denied Incyte Petition Challenging CTP-543 Patent,2017-10-19 13:01:00-04:00,INCY,negative
664958.0,Bank Of America Sees NewLink Genetics As 'Undervalued',2017-10-13 09:58:00-04:00,INCY,neutral
664959.0,Jim Cramer Gives His Opinion On Tripadvisor And Incyte,2017-09-26 07:34:00-04:00,INCY,neutral
664960.0,RBC Initiated Coverage On 33 Pharma/Biotech Cos.,2017-09-15 07:38:00-04:00,INCY,neutral
664961.0,Eli Lilly's Baricitinib Meets Primary Endpoint in Phase 2 Study of Patients with Moderate-to-Severe Atopic Dermatitis,2017-09-14 09:06:00-04:00,INCY,neutral
664962.0,"Pro: Even At 205 Times Earnings, Amazon's Stock Is Still Attractive",2017-09-12 14:45:00-04:00,INCY,positive
664963.0,This Analyst Predicts Bullish Growth Outlook For Incyte,2017-09-12 09:28:00-04:00,INCY,positive
664964.0,"Benzinga's Top Upgrades, Downgrades For September 11, 2017",2017-09-11 09:13:00-04:00,INCY,positive
664965.0,"Raymond James Upgrades Incyte to Outperform, Announces $159.00 Price Target",2017-09-11 08:12:00-04:00,INCY,neutral
664966.0,"Incyte, Merck Announce Positive Progression-Free Survival Data from ECHO-202 Trial of Epacadostat in Combination with KEYTRUDA in Patients with Advanced Melanoma at ESMO 2017",2017-09-09 10:41:00-04:00,INCY,positive
664967.0,STAT News' Adam Feuerstein Tweets '$INCY priced at $132',2017-09-08 09:28:00-04:00,INCY,neutral
664968.0,"European Society for Medical Oncology(ESMO) 2017 Congress Begins Today, Day 1 Of 5",2017-09-08 09:15:00-04:00,INCY,neutral
664969.0,"Incyte Prices 4.945M Share Offering, Price Not Disclosed",2017-09-08 08:35:00-04:00,INCY,positive
664970.0,Incyte Announces Offering 4.945M Shares Common Stock,2017-09-07 17:28:00-04:00,INCY,positive
664971.0,Watch These 8 Huge Put Purchases In Wednesday Trade,2017-09-06 04:15:00-04:00,INCY,positive
664972.0,Benzinga's Option Alert Recap From September 5,2017-09-05 16:21:00-04:00,INCY,positive
664973.0,Incyte Option Alert: Jun 15 $125 Puts Sweep (2) at the Ask: 700 @ $15.2 vs 0 OI; Ref=$135.09,2017-09-05 14:53:00-04:00,INCY,positive
664974.0,Incyte Announces New Data for Epacadostat in Combination with KEYTRUDA Demonstrate Durable Responses in Patients with Advanced Melanoma,2017-08-31 04:28:00-04:00,INCY,positive
664975.0,"UPDATE: Lilly, Incyte Expect FDA To Classify NDA For Baricitinib As Class I Resubmission, Which Will Start A New 6-Month Review Cycle",2017-08-30 06:47:00-04:00,INCY,neutral
664976.0,"Eli Lilly, Incyte Report Will Resubmit NDA For Baricitinib Before End Of Jan. '18",2017-08-30 06:45:00-04:00,INCY,neutral
664977.0,"Evercore ISI Group Initiates Coverage On Incyte with In-Line Rating, Announces $135.00 Price Target",2017-08-17 07:23:00-04:00,INCY,neutral
664978.0,Incyte Pharma Gives Guidance Update,2017-08-01 07:10:00-04:00,INCY,neutral
664979.0,"Incyte Q2 EPS $(0.06) vs $(0.03) Est., Sales $326.44M vs $315.40M Est.",2017-08-01 07:09:00-04:00,INCY,neutral
664980.0,Eli Lilly and Incyte's Re-submission of a New Drug Application to the FDA Will be Delayed Beyond 2017,2017-07-25 06:16:00-04:00,INCY,negative
664981.0,Incyte Reports First Patient Was Treated In Phase 3 Trial Of Itacitinib For Acute Graft-Versus-Host Disease,2017-07-20 07:40:00-04:00,INCY,neutral
664982.0,Incyte Sees Upgrade From Vetr Crowd,2017-07-18 09:23:00-04:00,INCY,neutral
664983.0,UPDATE: Lilly Says Japanese Marketing Authorization Of Olumiant Triggered $15M Milestone Payment From Lilly To Incyte,2017-07-03 08:02:00-04:00,INCY,neutral
664984.0,Eli Lilly and Incyte Announce Japan's Ministry of Health Grants Marketing Approval for Olumiant,2017-07-03 08:02:00-04:00,INCY,positive
664986.0,"Lilly, Incyte Announce Results from Long-term Extension of Phase 3 Studies Show Treatment With Baricitinib Slows Progression of Joint Damage, Controls Disease Activity over 2 Years #EULAR2017",2017-06-16 04:24:00-04:00,INCY,negative
664987.0,"William Blair Growth Stock Conference Continues Today; Carvana, E.L.F. Beauty, Booz Allen, Envision Healthcare, Zebra Technologies, Wayfair, Incyte, Zendesk, Mastercard, Twilio, Lululemon, and American Express",2017-06-14 08:08:00-04:00,INCY,positive
664988.0,"Lilly, Incyte Announce Presentation of New Data on Olumiant in RA, Taltz in PsA at #EULAR 2017",2017-06-13 18:07:00-04:00,INCY,neutral
664989.0,This Biotech Name Could Be Best In Breed For 2017,2017-06-13 08:46:00-04:00,INCY,positive
664991.0,"3 Takeaways From Monday's ASCO Meetings: Puma Biotech, Incyte, Celgene",2017-06-06 16:34:00-04:00,INCY,neutral
664992.0,Incyte and Bristol-Myers Give Update on Phase 1/2 ECHO Trial,2017-06-05 07:31:00-04:00,INCY,neutral
664993.0,Combination of Incyte's Epacadostat + Merck's KEYTRUDA Demonstrates Activity in Clinical Trial of Patients with Advanced Non-Small Cell Lung Cancer #ASCO17,2017-06-03 11:39:00-04:00,INCY,negative
664994.0,@adamfeuerstein Tweet:  $INCY 'IDO' Combination Lung Cancer Results Improve Slightly at #ASCO17 $MRK —> thestreet.com/story/14161405,2017-06-03 09:07:00-04:00,INCY,negative
664995.0,"Companies Holding Shareholder Meetings Today Include: Incyte, Sunrun, Lincoln National, & Drive Shack",2017-05-26 09:34:00-04:00,INCY,neutral
664996.0,The Most Notable Abstracts Released Ahead Of ASCO 2017,2017-05-19 08:21:00-04:00,INCY,neutral
664997.0,15 Biggest Mid-Day Gainers For Thursday,2017-05-18 12:31:00-04:00,INCY,neutral
664998.0,25 Stocks Moving In Thursday's Pre-Market Session,2017-05-18 08:09:00-04:00,INCY,neutral
664999.0,Incyte Says First Data from Combo of Epacadostat with Bristol-Myers' Opdivo Shows Combo is 'well-tolerated and demonstrates promising clinical outcomes in multiple advanced solid tumors',2017-05-17 17:17:00-04:00,INCY,positive
665000.0,Incyte Issues Release Highlighting Co.'s IDO1 Enzyme Inhibitor in Combo with Merck's Anti-PD-1 Therapy is 'well-tolerated and demonstrates durable clinical responses across multiple solid tumors',2017-05-17 17:03:00-04:00,INCY,positive
665001.0,"Benzinga's Top Upgrades, Downgrades For May 12, 2017",2017-05-12 09:21:00-04:00,INCY,positive
665002.0,"Oppenheimer Initiates Coverage On Incyte with Market Perform Rating, Announces $125.00 Price Target",2017-05-12 07:56:00-04:00,INCY,neutral
665003.0,Near-Term Events Cast Shadow Of Uncertainty On Bristol-Myers,2017-05-06 09:03:00-04:00,INCY,negative
665004.0,"Incyte, Lilly Disagree With FDA CRL for Baricitinib; Expects Lilly to Engage With FDA to Discuss Agency's Concerns, Determine Potential Path Forward",2017-05-04 07:15:00-04:00,INCY,negative
665005.0,"Incyte Sees FY17 Jakafi Net Product Sales $1.02B-$1.07B, Iclusig Sales $60M-$65M",2017-05-04 07:10:00-04:00,INCY,neutral
665006.0,"Incyte Reports Q1 EPS $(0.96) vs $(1.00) Est., Sales $384.082M",2017-05-04 07:09:00-04:00,INCY,neutral
665007.0,Mark Your Calendar For These Days In May To Play The Volatility Around FDA Decision Dates,2017-04-25 13:44:00-04:00,INCY,positive
665008.0,"Earnings: Caterpillar, Lockheed Martin, and Eli Lilly Report Tomorrow",2017-04-24 13:45:00-04:00,INCY,neutral
665009.0,Mid-Afternoon Market Update: Crude Oil Down 1%; MOCON Shares Spike Higher,2017-04-17 15:02:00-04:00,INCY,negative
665010.0,15 Biggest Mid-Day Losers For Monday,2017-04-17 13:08:00-04:00,INCY,negative
665011.0,Mid-Day Market Update: Dow Surges Over 100 Points; Oncomed Shares Slide,2017-04-17 12:06:00-04:00,INCY,positive
665012.0,"Benzinga's Top Upgrades, Downgrades For April 17, 2017",2017-04-17 09:34:00-04:00,INCY,positive
665013.0,The Market In 5 Minutes,2017-04-17 09:21:00-04:00,INCY,neutral
665014.0,20 Stocks Moving In Monday's Pre-Market Session,2017-04-17 08:24:00-04:00,INCY,neutral
665015.0,PiperJaffray Downgrades Incyte To Neutral,2017-04-17 07:56:00-04:00,INCY,neutral
665016.0,"Eli Lilly -4.7% Premarket @ $81.88, Incyte -12.7% @ $123; FDA on Friday Declined to Approve, Lilly, Incyte Arthritis Drug Olumiant",2017-04-17 06:29:00-04:00,INCY,neutral
665017.0,"Lilly, Incyte Announce FDA Issues CRL for Baricitinib",2017-04-14 09:02:00-04:00,INCY,neutral
665018.0,Your Cheat Sheet For Q1 Biotech Earnings,2017-04-06 12:47:00-04:00,INCY,negative
665019.0,Incyte Shares Dip Into Negative Territory Following Mid-Day Downgrade from Raymond James,2017-04-05 14:11:00-04:00,INCY,negative
665020.0,Feuerstein Throws BioMarin Into Gilead Takeover Speculation,2017-04-05 11:28:00-04:00,INCY,neutral
665021.0,"Bristol-Myers Squibb, Incyte Announce Agreement to Advance the Combination of Opdivo and Epacadostat into First-line Registrational Trials",2017-04-02 09:31:00-04:00,INCY,positive
665022.0,"UPDATE: Incyte, Merck Announce Clinical Program for Epacadostat, KEYTRUDA Includes 7 Registrational Trials Across 5 Tumor Types",2017-03-31 07:08:00-04:00,INCY,negative
665023.0,"Incyte, Merck Offer Added Details on Previously Announced Collab. Investigating Epacadostat, KEYTRUDA",2017-03-31 07:08:00-04:00,INCY,neutral
665024.0,Incyte Shares Spike Over $148 Level as Hearing Traders Circulating Unconfirmed Chatter of Gilead Interest,2017-03-16 14:26:00-04:00,INCY,positive
665025.0,"Barclays Global Healthcare Conference Continues Today; Presenters Include HCA Holdings, Valeant, Incyte, Celgene, Cotiviti, Aetna, Anthem, Seattle Genetics, Teva Pharma, Pfizer, & Bristol-Myers",2017-03-15 08:25:00-04:00,INCY,neutral
665026.0,Gilead Looking To Buy Incyte? It Makes Sense,2017-03-14 10:55:00-04:00,INCY,neutral
665027.0,Incyte Shares Down 3.16% After Hours,2017-03-13 16:36:00-04:00,INCY,positive
665028.0,Adam Feuerstein Tweets: Barclays Healthcare Conference: $GILD CEO John Milligan 9 am Tues. $INCY CEO Herve Hoppenot 2:30 pm Weds. Both STILL ON SCHEDULE.,2017-03-13 08:52:00-04:00,INCY,neutral
665029.0,Wall Street's M&A Chatter From March 10-12,2017-03-13 07:01:00-04:00,INCY,neutral
665030.0,"TheStreet's Adam Feuerstein Tweets '$INCY just registered to sell 34M shares on behalf of Baker Brothers. Basically, their entire stake. Doesn't mean BB will sell but they can.",2017-03-10 21:01:00-05:00,INCY,positive
665031.0,Incyte Spikes to High of $149.28,2017-03-10 15:47:00-05:00,INCY,neutral
665032.0,Hearing Unconfirmed Chatter Gilead Near Bid for Incyte,2017-03-10 15:23:00-05:00,INCY,negative
665033.0,"Happy Birthday, Bull Market - Here Are The Biggest Winners And Losers Over The Past 8 Years",2017-03-09 15:15:00-05:00,INCY,positive
665034.0,"Benzinga's Top Upgrades, Downgrades For March 9, 2017",2017-03-09 09:42:00-05:00,INCY,positive
665035.0,"UBS Initiates Coverage On Incyte With Neutral, Announces $140 Price Target",2017-03-09 06:18:00-05:00,INCY,neutral
665036.0,"Cowen Annual Healthcare Conference Concludes Today; Presenters Include Agilent Tech, Incyte, GW Pharma, Teva Pharma, NantKwest, Seattle Genetics, And Celgene",2017-03-08 08:25:00-05:00,INCY,neutral
665037.0,Nomura Initiates Coverage On Incyte at Buy,2017-03-02 07:26:00-05:00,INCY,neutral
665038.0,UPDATE: Incyte Will Replace Spectra Energy,2017-02-23 17:20:00-05:00,INCY,positive
665039.0,"S&P Dow Jones Indices Announces Incyte, CBOE, Regency Centers to Join S&P 500",2017-02-23 17:19:00-05:00,INCY,positive
665040.0,Incyte Reports Oncology Research Alliance with the Abramson Cancer Center at the University of Pennsylvania,2017-02-23 07:59:00-05:00,INCY,negative
665041.0,"Incyte Reports Julian Baker Entities Agreed to Exchange $259M of Co's 0.375% Notes Due 2018,$274.5M of Co's 1.25% Notes Due 2020",2017-02-21 07:15:00-05:00,INCY,positive
665042.0,Eli Lilly & Incyte Announce Add'l Results From Pivotal RA-BEAM Study In New England Journal Of Medicine,2017-02-15 18:00:00-05:00,INCY,neutral
665043.0,5 Biggest Price Target Changes For Wednesday,2017-02-15 11:25:00-05:00,INCY,neutral
665044.0,18 Biggest Mid-Day Gainers For Tuesday,2017-02-14 12:28:00-05:00,INCY,neutral
665045.0,Agenus Gets A Boost From Incyte Cash Infusion,2017-02-14 11:57:00-05:00,INCY,positive
665046.0,20 Stocks Moving In Tuesday's Pre-Market Session,2017-02-14 08:33:00-05:00,INCY,neutral
665047.0,Adam Feuerstein Tweets: $AGEN forced to amend its cancer immunotherapy collaboration w/ $INCY bc co. needs money now. Shows lack of confidence.,2017-02-14 07:17:00-05:00,INCY,negative
665048.0,Incyte Sees FY17 Jakafi Net Product Sales $1.02B-$1.07B,2017-02-14 07:06:00-05:00,INCY,neutral
665049.0,"Incyte Reports Q4 EPS $0.05 vs $0.29 in Same Qtr. Last Year, Total Sales $326M vs $324M Est.",2017-02-14 07:06:00-05:00,INCY,neutral
665050.0,UPDATE: Agenus Will Receive $80M from Incyte,2017-02-14 07:02:00-05:00,INCY,neutral
665051.0,"Incyte, Agenus Report Amended Collaboration Deal for Development, Commercialization Responsibilities for GITR, OX40 Programs",2017-02-14 07:02:00-05:00,INCY,neutral
665052.0,"Earnings Scheduled For February 14, 2017",2017-02-14 04:49:00-05:00,INCY,neutral
665053.0,"UPDATE: Eli Lilly Says, As a Result of Olumiant Approval by EC, Incyte Becomes Eligible to Receive $65M Milestone Payment",2017-02-13 16:24:00-05:00,INCY,positive
665054.0,Mid-Afternoon Market Update: Tempur Sealy Drops After Loss Of Mattress Firm Contract; Digital Ally Shares Surge,2017-01-30 14:30:00-05:00,INCY,neutral
665055.0,15 Biggest Mid-Day Gainers For Monday,2017-01-30 12:23:00-05:00,INCY,neutral
665056.0,Mid-Day Market Update: Dow Falls Over 150 Points; Calithera Biosciences Shares Spike Higher,2017-01-30 12:06:00-05:00,INCY,positive
665057.0,Mid-Morning Market Update: Markets Open Lower; Booz Allen Profit Misses Estimates,2017-01-30 10:09:00-05:00,INCY,negative
665058.0,25 Stocks Moving In Monday's Pre-Market Session,2017-01-30 08:28:00-05:00,INCY,neutral
665059.0,"Incyte, Calithera Biosciences Report Global Collaboration for Development, Commercialization of CB-1158",2017-01-30 06:49:00-05:00,INCY,neutral
665060.0,"Merus Reports Closing of Collab Deal with Incyte for Discovery, Development of Bispecific Antibodies; Incyte to Pay Merus Upfront Payment of $120M, Purchase 3.2M Shares of MRUS at $25/Share",2017-01-23 16:07:00-05:00,INCY,positive
665061.0,"Benzinga's Top Upgrades, Downgrades For January 23, 2017",2017-01-23 09:13:00-05:00,INCY,positive
665062.0,"Barictinib FDA Delay Only A 'Short-Term Setback' For Eli Lilly, Says Credit Suisse",2017-01-17 09:14:00-05:00,INCY,positive
665063.0,"Incyte PDUFA Date Pushed Back, JMP Discusses Impact",2017-01-17 08:13:00-05:00,INCY,neutral
665064.0,"Eli Lilly And Incyte Report FDA Has Extended Review Period For Baricitinib, PUDFA Goal Date Has Been Extended By 3 Months",2017-01-13 16:53:00-05:00,INCY,neutral
665065.0,7 Biotech Catalysts Remaining In January,2017-01-13 14:08:00-05:00,INCY,neutral
665066.0,"JP Morgan Healthcare Conf. Begins Today; Presenters Include Insulet, Teladoc, Incyte, Johnson & Johnson, Acadia Healthcare, & Teva Pharmaceuticals",2017-01-09 08:49:00-05:00,INCY,positive
665067.0,"Incyte, Merck to Advance Clinical Development Program Investigating the Combination of Epacadostat with KEYTRUDA",2017-01-09 08:11:00-05:00,INCY,neutral
665068.0,Jefferies' Picks For 2017's Most And Least Likely Biotech M&A Targets,2017-01-05 16:10:00-05:00,INCY,neutral
665069.0,"Incyte, TESARO, BioMarin Shares Lower, Neurocrine Bio Shares Higher; Hearing Jefferies Classified Cos. as 'Most Favored M&A Targets'",2017-01-05 11:48:00-05:00,INCY,positive
665070.0,Incyte Announces First Patient Treated in Pivotal Clinical Trial Program for Ruxolitinib (Jakafi®) in Graft-versus-Host Disease,2016-12-30 16:15:00-05:00,INCY,neutral
665071.0,A Preview Of January PDUFA Dates,2016-12-28 11:10:00-05:00,INCY,neutral
665072.0,"The Najarian Brothers, On CNBC, Say They Are Long Incyte, Apple",2016-12-27 12:46:00-05:00,INCY,neutral
665073.0,Merus NV Executives Discuss Products And Plans Going Into 2017: 'We Have Milestones Coming Up',2016-12-23 10:19:00-05:00,INCY,neutral
665074.0,Merus CEO Explains The Incyte Agreement: 'This Deal Is Strategic For Both',2016-12-22 12:26:00-05:00,INCY,positive
665075.0,Mid-Afternoon Market Update: Crude Oil Down 1.5%; Merus Shares Spike Higher,2016-12-21 14:42:00-05:00,INCY,negative
665076.0,12 Biggest Mid-Day Gainers For Wednesday,2016-12-21 12:42:00-05:00,INCY,neutral
665077.0,Mid-Day Market Update: InvenSense Climbs After Acquisition News; Merrimack Shares Drop,2016-12-21 12:31:00-05:00,INCY,neutral
665078.0,Mid-Morning Market Update: Markets Edge Lower; Finish Line Misses Q3 Expectations,2016-12-21 09:57:00-05:00,INCY,negative
665079.0,20 Stocks Moving In Wednesday's Pre-Market Session,2016-12-21 08:25:00-05:00,INCY,neutral
665080.0,Merus +60% Premarket @$22.76; Co to Receive Up-Front Payment of $120M from Incyte; Sell $80M of Merus Shares,2016-12-21 08:16:00-05:00,INCY,positive
665081.0,"Incyte, Merus Announce Global Strategic Research Collaboration to Discover and Develop Bispecific Antibodies; Incyte To Make Up-Front Payment Of $120M And Purchase $80M Merus Shares",2016-12-21 07:04:00-05:00,INCY,positive
665082.0,Biotech Stocks Convalescing After Wednesday's Trump-Inspired Biotech Selloff,2016-12-08 09:53:00-05:00,INCY,neutral
665083.0,What Is The ASH Conference And Why Should Biotech Investors Care?,2016-12-05 12:16:00-05:00,INCY,positive
665084.0,Incyte Announces Pooled Analysis of Five-Year Data from Two Phase 3 Studies Further Supports Overall Survival Advantage Observed in Patients with Myelofibrosis Treated With Jakafi,2016-12-04 17:06:00-05:00,INCY,positive
665085.0,Agenus Announces Commencement of Phase 1/2 Clinical Trial of anti-OX40 Checkpoint Antibody INCAGN1949 in Patients with Solid Tumors,2016-11-30 08:51:00-05:00,INCY,positive
665086.0,"PiperJaffray Healthcare Conference Begins Today, Day 1 of 2; Presenters Include NantKwest, Ignyta, Gilead Sciences, DexCom, Incyte, bluebird bio",2016-11-29 08:53:00-05:00,INCY,neutral
665087.0,How Incyte Just Became A Major M&A Target,2016-11-17 13:10:00-05:00,INCY,neutral
665088.0,"Incyte Shares Trading Up 5.3%, Traders Attributing Strength To Multiple Analyst Notes Highlighting Gilead's Unlikely Approval Of SIMPLIFY-1 and SIMPLIFY-II, Combined With Repatriation Holiday, Make Incyte More Attractive As M&A Target",2016-11-17 11:10:00-05:00,INCY,positive
665089.0,Incyte Phase 2 Data On Topical Ruxolitinib In Alopecia Presented At National Alopecia Areata Foundation Reseaarch Summit Today,2016-11-14 11:59:00-05:00,INCY,neutral
665090.0,"Eli Lilly, Incyte Corp Report RA-BEAM and Ra-BUILD Patients Early Response To Baricitinib Show Significant Improvement Compared To Adalimummab In Patient-Reported Outcomes",2016-11-14 09:05:00-05:00,INCY,positive
665091.0,"Adam Feuerstein Tweets: $GILD Next Challenge to $INCY Myelofibrosis Drug Dominance thestreet.com/story/13885447… Momelotinib ph3 preview, to distract from u know what.",2016-11-08 13:55:00-05:00,INCY,neutral
665092.0,Incyte Sells off to Low of $90.46 on Volume,2016-11-08 13:53:00-05:00,INCY,negative
665093.0,"Eli Lilly, Incyte Reports New Data from Pivotal RA-BEACON Study Showing Significant Improvement in Patient-Reported Outcomes in RA Patients Treated with Baricitinib vs Placebo",2016-11-02 12:24:00-04:00,INCY,positive
665094.0,"Incyte Q3 EPS $0.19 vs $(0.01) Est, Revenue $269.5M vs $261.4M Est",2016-11-01 07:08:00-04:00,INCY,neutral
665095.0,"Incyte Shares Recently Pulled Back from $88 Level; Hearing News Astra, FDA Made Deal for Partial Clinical Hold is Negative for Incyte",2016-10-27 11:42:00-04:00,INCY,negative
665096.0,Incyte Sells Off to Low of $89.80 on Volume,2016-10-11 14:35:00-04:00,INCY,negative
665097.0,Rich Ross Shares His Biotech Trades,2016-10-11 06:32:00-04:00,INCY,positive
665098.0,The Street Is Seeing Higher Probability Of Success For Incyte's Melanoma Treatment,2016-10-10 12:08:00-04:00,INCY,positive
665099.0,Incyte Announces Updated Data from Phase I Portion of ECHO-202 Trial Evaluating Safety and Efficacy of Epacadostat in combination with Keytruda,2016-10-07 04:49:00-04:00,INCY,positive
665100.0,Benzinga's Top Upgrades,2016-09-29 08:42:00-04:00,INCY,positive
665101.0,Raymond James Upgrades Incyte to Outperform,2016-09-29 06:14:00-04:00,INCY,neutral
665102.0,Merck Shares Indicated Up 1+% Premarket; Shares Could Be Higher Amid Positive Trial News from Incyte; Incyte Shares Up ~5% in Pre-Open,2016-09-28 08:17:00-04:00,INCY,positive
665103.0,Incyte Announces Updated Phase 1 Data Reinforce Clinical Profile of Epacadostat in Combination with Keytruda,2016-09-28 06:13:00-04:00,INCY,neutral
665104.0,Incyte Corp Reports NCCN Guidelines Recommend Jakafi For Treatment Of MF,2016-09-27 07:46:00-04:00,INCY,positive
665105.0,"Incyte Could Be A Takeover Target, Argus Lifts Price Target To $98",2016-09-26 12:40:00-04:00,INCY,neutral
665106.0,10 Stocks Which Rallied Three Days On Increasing Volume,2016-09-19 09:26:00-04:00,INCY,neutral
665107.0,"Janney Initiates Galapagos At Buy, Sees Fair Value Of Shares At $64",2016-08-30 12:16:00-04:00,INCY,positive
665108.0,Incyte Raises FY 2016 Guidance,2016-08-09 07:02:00-04:00,INCY,neutral
665109.0,"Incyte Q2 EPS $0.18 vs ($0.02) est, Revenue $246.3M vs $235.2M est",2016-08-09 07:01:00-04:00,INCY,neutral
665110.0,Benzinga's Top Initiations,2016-08-05 09:30:00-04:00,INCY,positive
665111.0,SunTrust Robinson Humphrey Initiates Coverage on Incyte at Buy,2016-08-05 07:02:00-04:00,INCY,neutral
665112.0,7 Biggest Price Target Changes For Monday,2016-08-01 09:48:00-04:00,INCY,neutral
665113.0,Option Alert: INCY Sep16 95.0 Calls Sweep: 767 @  ASK  $3.40: 1413 traded vs 52 OI:  Earnings 8/9 Before Open  $86.18 Ref,2016-07-20 12:02:00-04:00,INCY,positive
665114.0,"Incyte, Seattle Genetics Seen as Possible Acquisition Targets for their Cancer Treatments -Reuters",2016-07-19 04:52:00-04:00,INCY,negative
665115.0,Benzinga's Top Initiations,2016-07-13 09:23:00-04:00,INCY,positive
665116.0,RBC Capital Initiates Coverage on Incyte at Outperform,2016-07-13 07:17:00-04:00,INCY,neutral
665117.0,"9 Stocks Haunted By Brexit, Creating Unwarranted Drops",2016-06-29 15:40:00-04:00,INCY,negative
665118.0,"Amgen, Incyte Well Positioned Following Brexit",2016-06-29 09:49:00-04:00,INCY,positive
665119.0,Incyte Gets FDA Approval For Breakthrough Therapy Status For Its Ruxolitinib,2016-06-23 09:11:00-04:00,INCY,positive
665120.0,Incyte Corp. Reports FDA Grants Breakthrough Therapy Designation for Incyte's Ruxolitinib in Acute Graft-Versus-Host Disease,2016-06-23 07:30:00-04:00,INCY,positive
665121.0,Incyte Announces New Phase 3 Data Show Jakafi is Superior to Best Available Therapy in Patients with Polycythemia Vera at EHA,2016-06-10 04:11:00-04:00,INCY,positive
665122.0,Eli Lilly and Incyte Say Two Phase 3 Trials For Arthritis Have Positive Results,2016-06-09 06:48:00-04:00,INCY,positive
665123.0,"Incyte Corp. Reports 31% Reduction In Risk Of Death In Jakafi vs. Placebo, 59% Of Patient Population (92/155) Showed 35% Reduction In Spleen Volume In 5 Year Study",2016-06-06 07:37:00-04:00,INCY,negative
665124.0,"Incyte Reports Q1 EPS $0.12 vs. Est. $0.20, Rev. $263.46M vs. Est. $263.9M",2016-05-09 07:17:00-04:00,INCY,neutral
665125.0,Incyte to Acquire ARIAD's European Operations for $140M,2016-05-09 07:04:00-04:00,INCY,neutral
665126.0,"Incyte Announces Richard S. Levy, Executive VP and Chief Drug Development Officer Intends to Retire Effective April 30",2016-04-18 07:38:00-04:00,INCY,positive
665127.0,BMO Capital Initiates Coverage on Incyte at Outperform,2016-04-07 06:29:00-04:00,INCY,neutral
665128.0,"After-Hours Recap: Bed Bath & Beyond, Apollo, Valeant, eBay & More",2016-04-06 18:36:00-04:00,INCY,neutral
665129.0,"Incyte Acquires Rights To Devlop and Commercialize Ruxolitinib From Lilly, Will Make $35M Upfront Payment As Well As Additional Potential Payments Contingent On Certain Regulatory Milestones; Novartis Granted Right To Develop & Commercialize Ruxolitinib",2016-04-06 07:31:00-04:00,INCY,positive
665130.0,"Eli Lilly Phase 3 Show Baricitinib Treatment With Patients In Rheumatoid Arthritis Show Significant Improvements, Met Primary Endpoint",2016-03-31 07:01:00-04:00,INCY,positive
665131.0,Mid-Day Market Update: Crude Oil Down 2.8%; KB Home Shares Surge Following Strong Results,2016-03-24 12:15:00-04:00,INCY,positive
665132.0,Aduro Biotech Reports Initial Patient Dosed in Combination Clinical Trial of CRS-207 and Epacadostat to Treat Ovarian Cancer,2016-03-24 08:01:00-04:00,INCY,negative
665133.0,Benzinga's Top Initiations,2016-03-23 08:41:00-04:00,INCY,positive
665134.0,"Morgan Stanley Initiates Coverage on Incyte at Overweight, Announces $85.00 PT",2016-03-23 03:51:00-04:00,INCY,negative
665135.0,"Baker Bros. Reports 12.6% Stake In Incyte as of March 17, 2016",2016-03-17 17:24:00-04:00,INCY,neutral
665136.0,"Incyte's Monoclonal Antibody Agonist Programs Targeting GITR, OX40, LSD1, BRD (BET), PI3Kδ and JAK1 To Be Featured at the AACR Annual Meeting 2016",2016-03-16 16:38:00-04:00,INCY,neutral
665137.0,Agenus Shares Spike Higher Following Mid-Day Upgrade To Buy From Maxim,2016-03-12 12:04:00-05:00,INCY,positive
665138.0,"The Stocks That Moved The S&P, Dow And Nasdaq Today",2016-03-09 16:30:00-05:00,INCY,neutral
665139.0,The 10 Most Notable Insider Transactions Last Week,2016-02-22 12:17:00-05:00,INCY,neutral
665140.0,"Julian Baker Buys 2,251,427 Shares of Incyte Corp  @$63.50/Share -Form 4",2016-02-16 20:19:00-05:00,INCY,positive
665141.0,"Brean Capital Maintains Buy on Incyte, Lowers PT to $92.00",2016-02-12 05:25:00-05:00,INCY,negative
665142.0,"Barclays Maintains Overweight on Incyte, Lowers PT to $85.00",2016-02-12 04:11:00-05:00,INCY,negative
665143.0,Mid-Day Market Update: Dow Drops Over 300 Points; Cisco Shares Surge Following Strong Q2 Results,2016-02-11 12:38:00-05:00,INCY,positive
665144.0,Mid-Morning Market Update: Markets Open Lower; PepsiCo Posts In-Line Q4 Profit,2016-02-11 09:48:00-05:00,INCY,positive
665145.0,12 Stocks Moving In Thursday's Pre-Market Session,2016-02-11 08:24:00-05:00,INCY,neutral
665146.0,Incyte Sees FY16 Jakafi Sales $800M-$815M,2016-02-11 07:12:00-05:00,INCY,neutral
665147.0,"Incyte Reports Q4 EPS $0.30 vs $(0.22) in Same Qtr. Last Year, Sales $182M vs $226M Est.",2016-02-11 07:12:00-05:00,INCY,neutral
665148.0,Mid-Afternoon Market Update: Dow Rises Over 100 Points; eBay Shares Drop On Disappointing Outlook,2016-01-28 14:31:00-05:00,INCY,negative
665149.0,Mid-Day Market Update: Facebook Surges On Strong Results; ServiceNow Shares Slip,2016-01-28 12:00:00-05:00,INCY,positive
665150.0,"Incyte To Stop A Phase 2 Sub-Study, Shares Lose 10%",2016-01-28 11:46:00-05:00,INCY,negative
665151.0,"Street Likes Incyte & Vertex After Drug Trial, Earnings Update",2016-01-28 11:12:00-05:00,INCY,positive
665152.0,Mid-Morning Market Update: Markets Open Higher; Ford Tops Q4 Views,2016-01-28 10:06:00-05:00,INCY,positive
665153.0,Incyte Shares Fall as Low as $59.93 After-Hours Following Announcement of Decision to Stop Phase 2 Sub-Study Of RuxolitinibPlus Regorafenib,2016-01-27 16:46:00-05:00,INCY,negative
665154.0,"Incyte To Stop Phase 2 Sub-Study Of RuxolitinibPlus Regorafenib, Did Not Show Sufficient Level Of Efficacy To Warrant Continuation",2016-01-27 16:43:00-05:00,INCY,negative
665155.0,Credit Suisse Bullish On Most Big Pharma Names,2016-01-20 10:34:00-05:00,INCY,positive
665156.0,Benzinga's Top Initiations,2016-01-20 09:46:00-05:00,INCY,positive
665157.0,"Credit Suisse Initiates INCY At Outperform, Upside Catalysts Are Baracitnib Royalties, Opportunity For Jakafi's PV Indication, And Valuable Pipeline",2016-01-20 05:51:00-05:00,INCY,positive
665158.0,"Credit Suisse Initiates Coverage on Incyte at Outperform, Announces $110.00 PT",2016-01-19 16:20:00-05:00,INCY,positive
665159.0,"Eli Lilly, Incyte Report Submission of NDA for Oral Once-Daily Baricitinib for Treatment of Moderate-to-Severe RA",2016-01-19 08:05:00-05:00,INCY,neutral
665160.0,Incyte and AstraZeneca Announce New Lung Cancer Clinical Trial Collaboration,2016-01-11 07:00:00-05:00,INCY,negative
665161.0,Incyte Spikes to High  of $105.98 on Volume,2016-01-05 13:29:00-05:00,INCY,neutral
665162.0,Benzinga's Top Initiations,2016-01-05 09:54:00-05:00,INCY,positive
665163.0,Raymond James Initiates Coverage on Incyte at Market Perform,2016-01-05 08:22:00-05:00,INCY,neutral
665164.0,Incyte Announces Two Phase 3 Studies Show Sustained Benefits of Jakafi in Patients with Myeloproliferative Neoplasms (MPNs),2015-12-05 10:22:00-05:00,INCY,positive
665165.0,Incyte Announces Phase 3 RESPONSE-2 Study of Jakafi Meets Primary Endpoint,2015-12-05 10:20:00-05:00,INCY,neutral
665166.0,Goldman Sees 2016 'Flight To Quality' In These Biotech Stocks,2015-11-18 11:05:00-05:00,INCY,neutral
665167.0,"Goldman Sachs Initiates Coverage on Incyte at Buy, Announces $135.00 PT",2015-11-18 06:44:00-05:00,INCY,neutral
665168.0,"Lilly, Incyte Announce Data Demonstrate Baricitinib Superiority to Adalimumab in Improving Signs and Symptoms of RA",2015-11-07 20:04:00-05:00,INCY,positive
665169.0,Incyte Shares Bounce Big Off Circuit Breaker Halt,2015-11-06 13:51:00-05:00,INCY,positive
665170.0,"Oppenheimer Desk Comments On Incyte: Says Melanoma Data For IDO + PD1 Inhibitor Was Worse Than Initial Abstracts, Complete Response Fell From Prior August Data",2015-11-06 13:48:00-05:00,INCY,negative
665171.0,"Shares Of Incyte Halted For 2nd Time, Limit Up-Limit Down",2015-11-06 13:46:00-05:00,INCY,positive
665172.0,Incyte Corp. Resumes Trade,2015-11-06 13:42:00-05:00,INCY,neutral
665173.0,"UPDATE: Incyte Halt From Limit Up, Limit Down Volatility",2015-11-06 13:39:00-05:00,INCY,neutral
665174.0,Incyte Corp. Trading Halted,2015-11-06 13:38:00-05:00,INCY,neutral
665175.0,"NewLink Genetics Shares Falling, Hearing Weak IDO Keytruda Combo Data, Incyte Shares Continue To Selloff Also",2015-11-06 13:31:00-05:00,INCY,neutral
665176.0,"Shares Of Incyte Corp Sold Off ~$10, Traded Below $105, Unclear What The Catalyst Is, Currently Trading $107.26",2015-11-06 13:21:00-05:00,INCY,positive
665177.0,Incyte Shares Sell Off on Volume,2015-11-06 13:21:00-05:00,INCY,positive
665178.0,Epacadostat in Combination with Pembrolizumab Demonstrates Promising Clinical Activity in Multiple Advanced Cancers,2015-11-03 08:05:00-05:00,INCY,positive
665179.0,Incyte Raises FY15 Sales Outlook from $560M-$575M to $580M-$590M,2015-11-03 07:03:00-05:00,INCY,neutral
665180.0,"Incyte Reports Q3 EPS $(0.22) vs. Est. $(0.41), Rev. $187.611M vs. Est. $176.85M",2015-11-03 07:00:00-05:00,INCY,neutral
665181.0,Lilly and Incyte Announce Webcast to Discuss Baricitinib Phase 3 Data,2015-10-27 13:20:00-04:00,INCY,neutral
665182.0,Cowen: In Biotech Earnings We Trust,2015-10-19 10:02:00-04:00,INCY,positive
665183.0,Biotech ETFs Get More Refined With Debut Of Cancer Immunotherapy Fund,2015-10-14 14:09:00-04:00,INCY,negative
665184.0,Incyte and Eli Lilly Announce Baricitnib Results,2015-10-14 06:47:00-04:00,INCY,neutral
665185.0,"Incyte, Merck Increase Clinical Collaboration to Include Phase 3 Study Investigating the Combination of Epacadostat with Keytrudaas First-line Treatment for Advanced Melanoma",2015-10-13 07:30:00-04:00,INCY,positive
665186.0,Incyte and Merck Expand Clinical Collaboration to Include Phase 3 Study Investigating the Combination of Epacadostat with Keytruda® (pembrolizumab) as First-line Treatment for Advanced Melanoma,2015-10-13 07:30:00-04:00,INCY,positive
665187.0,Eli Lilly and Incyte Announce Positive Top Line Phase 3 Baricitnib Results,2015-09-29 06:48:00-04:00,INCY,positive
665188.0,Amgen And Biogen Lead Short Interest Surge In Biotechs,2015-09-14 16:01:00-04:00,INCY,positive
665189.0,Stocks Hitting 52-Week Highs,2015-09-11 10:12:00-04:00,INCY,neutral
665190.0,Biotech Investors Still Have Opportunity,2015-09-09 11:20:00-04:00,INCY,positive
665191.0,UBS: Biotech Will Continue To Outperform In 2015,2015-09-08 13:22:00-04:00,INCY,neutral
665192.0,Incyte Announces Global License Agreement with Jiangsu Hengrui Medicine for SHR-1210,2015-09-02 05:01:00-04:00,INCY,positive
665193.0,Benzinga's Top Initiations,2015-08-13 09:31:00-04:00,INCY,positive
665194.0,Pipeline Momentum Makes Biotech Stock Incyte Worth Watching,2015-08-13 07:10:00-04:00,INCY,positive
665195.0,"Barclays Initiates Coverage on Incyte at Overweight, Announces $125.00 PT",2015-08-13 06:01:00-04:00,INCY,negative
665196.0,"Incyte Corp Reports EPS $0.05 May Not Compare, Sales $162.984M Vs Est $153.21M",2015-08-04 07:01:00-04:00,INCY,neutral
665197.0,Immunovaccine Collaborates With Incyte to Evaluate Novel Immunotherapy Combination for Patients With Platinum-Sensitive Ovarian Cancer,2015-06-25 07:07:00-04:00,INCY,negative
665198.0,"Incyte EVP, Chief Commercial Officer Jim Daly to Leave at End of June for Personal Reasons",2015-06-19 07:05:00-04:00,INCY,negative
665199.0,JMP Sees A 'Negative Market Tone' In Biotechnology,2015-06-15 13:31:00-04:00,INCY,negative
665200.0,Lilly and Incyte unveil detailed data on two pivotal studies of baricitinib in rheumatoid arthritis,2015-06-10 08:02:00-04:00,INCY,neutral
665201.0,Benzinga's Top Initiations,2015-05-29 09:25:00-04:00,INCY,positive
665202.0,Bank of America Initiates Incyte With Buy,2015-05-29 08:27:00-04:00,INCY,neutral
665203.0,"Bank of America Initiates Coverage on Incyte at Buy, Announces $126.00 PT",2015-05-29 07:56:00-04:00,INCY,neutral
665204.0,Lilly and Incyte Announce Webcast to Discuss Baricitinib Phase III Data,2015-05-28 13:00:00-04:00,INCY,neutral
665205.0,Incyte Clinical Portfolio to Feature 23 Abstract Presentations at the 2015 ASCO and EHA Annual Meetings,2015-05-27 07:32:00-04:00,INCY,neutral
665206.0,"Incyte Corp Reports Q1 -$0.11 Vs Est -$0.10, Sales $159.3M Vs Est $155.21M",2015-04-30 07:06:00-04:00,INCY,neutral
665207.0,Biotech Investors: May 29th Could Be A Big Day,2015-04-21 14:39:00-04:00,INCY,neutral
665208.0,CAR-T Therapy Stocks Hit Hard Following AACR Data,2015-04-20 13:44:00-04:00,INCY,negative
665209.0,It's A Big Weekend For Biotech,2015-04-17 16:31:00-04:00,INCY,neutral
665210.0,Incyte Describes Emerging Development Pipeline Related to Eleven Abstracts at AACR,2015-04-17 07:39:00-04:00,INCY,neutral
665211.0,16 Biotech Catalysts SunTrust Is Tracking,2015-04-06 19:38:00-04:00,INCY,neutral
665212.0,US Stock Futures Edge Lower Ahead Of Housing Starts Data,2015-03-17 07:38:00-04:00,INCY,negative
665213.0,Incyte Announces Jakavi Receives EC Approval as First Targeted Therapy for Patients with Polycythemia Vera,2015-03-17 04:38:00-04:00,INCY,positive
665214.0,Eli Lilly Reports Baricitinib Found Superior to Placebo for Reducing RA Disease Activity,2015-02-23 07:07:00-05:00,INCY,positive
665215.0,"Lilly, Incyte Report Baricitinib Superior to Placebo in Reducing RA Disease Activity in Second Phase 3 Study",2015-02-23 07:02:00-05:00,INCY,positive
665216.0,UPDATE: Incyte Filing on Agenus Shows Language Discussing Standstill Provisions for Allowance of Co. to Acquire Up to 15% of Agenus's Outstanding Voting Shares,2015-02-20 16:13:00-05:00,INCY,positive
665217.0,13G Filing from Incyte on Agenus Shows 11% Stake,2015-02-20 16:12:00-05:00,INCY,neutral
665218.0,"Incyte Reports Q4 EPS -$0.22 Vs Est -$0.09, Sales $124.0M Vs Est $138.37M",2015-02-12 07:02:00-05:00,INCY,neutral
665219.0,Morning Market Gainers,2015-02-11 09:48:00-05:00,INCY,neutral
665220.0,"Advaxis, Incyte Collaborate to Evaluate Investigational Combination of Cancer Immunotherapies for Early Stage Cervical Cancer",2015-02-11 07:32:00-05:00,INCY,negative
665221.0,Incyte Earns $25M Payment; Jakavi Receives Approval By CHMP,2015-01-23 07:40:00-05:00,INCY,positive
665222.0,10 Biotech Stories You Might've Missed This Week,2015-01-15 13:18:00-05:00,INCY,negative
665223.0,From JP Morgan Webcast: Incyte Sees 2014 Revenue From Jakafi $350-360M,2015-01-12 11:50:00-05:00,INCY,positive
665224.0,Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 1,2015-01-12 08:55:00-05:00,INCY,neutral
665225.0,"Agenus Announces Partnership With Incyte, Up to $350M of Milestones",2015-01-09 07:03:00-05:00,INCY,neutral
665226.0,19 Lesser-Known Biotech Stocks With Robust Drug Pipelines,2014-12-31 08:59:00-05:00,INCY,positive
665227.0,"Lilly, Incyte Announce Phase 3 Trial of Baricitinib in Moderate to Severe Rheumatoid Arthritis Met Primary Endpoint",2014-12-09 07:17:00-05:00,INCY,negative
665228.0,3 Biotech ETFs Rally On Merger News,2014-12-08 17:43:00-05:00,INCY,neutral
665229.0,UPDATE: FDA Approves Jakafi,2014-12-04 10:57:00-05:00,INCY,positive
665230.0,FDA Approves Incyte's Jakafi,2014-12-04 10:55:00-05:00,INCY,positive
665231.0,FDA Approves Jakafi to Treat Patients With Chronic Type of Bone Marrow Disease,2014-12-04 10:48:00-05:00,INCY,positive
665232.0,"Bear Raid in Incyte Shares, Now Recovering; Incyte Spokesperson Says May be Attributed to Upcoming PDUFA Date of December 5, Which has been Previously Announced",2014-11-25 14:59:00-05:00,INCY,positive
665233.0,Incyte Spikes Lower,2014-11-25 14:46:00-05:00,INCY,negative
665234.0,1 Biotech Beast Worth Tracking,2014-11-12 12:08:00-05:00,INCY,positive
665235.0,"Goldman Sachs Upgrades Incyte Corporation to Neutral, Raises PT to $62.00",2014-10-31 05:44:00-04:00,INCY,neutral
665236.0,Incyte Corporation Reports Q3 EPS of $0.33 vs $0.00 Est; Revenue of $198.10M vs $149.92M Est,2014-10-30 07:01:00-04:00,INCY,neutral
665237.0,Bank Of America Q3 Small & Mid-Cap Biotech Preview,2014-10-20 16:58:00-04:00,INCY,neutral
665238.0,Incyte Appoints David Gryska As EVP & CFO,2014-10-17 08:00:00-04:00,INCY,neutral
665239.0,Incyte Reports Earn of $60M Milestone Related to Reimbursement of Jakavi in Europe,2014-10-02 07:34:00-04:00,INCY,neutral
665240.0,"SunTrust Robinson Humphrey Initiates Coverage on Incyte Corporation at Buy, Announces $71.00 PT",2014-09-04 16:37:00-04:00,INCY,neutral
665241.0,Incyte Shares Flat After FDA Accepted NDA and Granted Priority Review,2014-08-05 07:53:00-04:00,INCY,positive
665242.0,Incyte Corporation Reports Q2 EPS of $(0.22) Which May Not Compare $(0.01) Est; Revenue of $99.60M Which May Not Compare $131.63M Est,2014-07-31 07:11:00-04:00,INCY,neutral
665243.0,UPDATE: Incyte Partners With Genetech to Help With Trials,2014-07-30 08:43:00-04:00,INCY,positive
665244.0,Incyte Partners With Genetech to Help With Trials,2014-07-30 08:32:00-04:00,INCY,positive
665245.0,Incyte Announces Jakafi Product Label Expanded to Include Overall Survival Data and Additional Safety and Dosing Information ,2014-07-28 07:08:00-04:00,INCY,positive
665246.0,Incyt Announces  Ruxolitinib Study Did Not Meet Endpoints,2014-07-23 16:19:00-04:00,INCY,neutral
665247.0,UPDATE: Incyte Says Will Earn Added $60M Milestone with Added Country Approval,2014-07-08 07:39:00-04:00,INCY,positive
665248.0,"Incyte Announces $25M Milestone Payment for Approval of Jakavi in Japan, Will Receive Payment from Novartis",2014-07-08 07:34:00-04:00,INCY,positive
665249.0,Incyte Shares Move Lower; May be  Attributed to Street.com Article ,2014-06-11 09:58:00-04:00,INCY,neutral
665250.0,UPDATE: Incyte Announces Trial Met Endpoint,2014-06-03 10:48:00-04:00,INCY,neutral
665251.0,Watch Shares of Novartis Following News from Incyte,2014-06-03 10:47:00-04:00,INCY,positive
665252.0,"Incyte Announces Trial Met Endpoint, Jakafi Had Superior Control",2014-06-03 10:47:00-04:00,INCY,positive
665253.0,Incyte Announces Full Results from Proof-of-Concept Phase II RECAP Trial of Jakafi® (ruxolitinib) in Combination with Capecitabine in Patients with Metastatic Pancreatic Cancer,2014-06-02 14:17:00-04:00,INCY,negative
665254.0,"Incyte Announces Prelim Results of Phase I/II Immunotherapy, 42% Had Objective Response, 75% Had Disease Control",2014-06-02 14:16:00-04:00,INCY,neutral
665255.0,"Incyte Announced 42% Immunotherapy-Naive Patients Had Objective Response, 75% Showed Disease Control, Combo Generally Well Tolerated",2014-06-02 14:16:00-04:00,INCY,positive
665256.0,"Bristol-Myers Squibb, Incyte Enter Clinical Collaboration Agreement ",2014-05-27 07:04:00-04:00,INCY,positive
665257.0,UPDATE: Morgan Stanley Reiterates On Incyte On ASCO Abstracts,2014-05-15 10:14:00-04:00,INCY,neutral
665258.0,Benzinga's Top #PreMarket Losers,2014-05-15 08:22:00-04:00,INCY,negative
665259.0,"Incyte, MedImmune Collaborate on Immuno-Oncology Combination Clinical Trial ",2014-05-14 05:51:00-04:00,INCY,neutral
665260.0,"Surges In Biotech Short Interest (INCY, PCYC, REGN)",2014-05-11 16:35:00-04:00,INCY,positive
665261.0,"Nomura Maintains Buy on Incyte Corporation, Lowers PT to $90.00",2014-05-02 07:49:00-04:00,INCY,negative
665262.0,Incyte Corporation Reports Q1 EPS of $(0.21) vs $(0.17) Est; Revenue of $89.80M vs $97.86M Est,2014-05-01 07:16:00-04:00,INCY,neutral
665263.0,"Incyte Shares Rally Following Leerink's New Outperform Rating, $76 Price Target",2014-04-29 10:54:00-04:00,INCY,positive
665264.0,Biotech Stocks Hedge Funds Are Betting On,2014-04-25 17:18:00-04:00,INCY,neutral
665265.0,"Mid-Day Losers Mar. 7, 2014: PXLW, ALOG, ALSK, NMRX, NLNK, EMAN",2014-03-07 11:34:00-05:00,INCY,negative
665266.0,"Morning Movers for Mar. 7, 2014: SKUL, DLIA, BIG, GTAT, CCRN, FL Moving Higher; NLNK, FEYE, SWY, FCEL Lower",2014-03-07 09:04:00-05:00,INCY,negative
665267.0,US Stock Futures Edge Higher; All Eyes On Jobs Report,2014-03-07 07:37:00-05:00,INCY,neutral
665268.0,Incyte Announces Positive Top-Line Results from Phase III Study of Ruxolitinib in Patients with Polycythemia Vera ,2014-03-07 05:37:00-05:00,INCY,positive
665269.0,UPDATE: Bank of America Reinstates Coverage on Incyte on Two Oncology Platforms,2014-02-26 08:19:00-05:00,INCY,neutral
665270.0,"Bank of America Assumes Incyte Corporation at Buy, Announces $84.00 PO",2014-02-26 07:00:00-05:00,INCY,negative
665271.0,"BioMarin Bucks Biotech Short Interest Trend (BIIB, BMRN, MDVN)",2014-02-13 10:18:00-05:00,INCY,positive
665272.0,Incyte Corporation Reports Q4 EPS of $(0.15) vs $(0.11) Est,2014-02-12 07:05:00-05:00,INCY,neutral
665273.0,Incyte Confirms Clinical Trial Collaboration with Merck to Evaluate Combination of Two Novel Immunotherapies ,2014-02-05 06:54:00-05:00,INCY,positive
665274.0,"Merck Confirms Collaborations with Amgen, Incyte and Pfizer to Evaluate Novel Combination Anti-cancer Regimens with MK-3475 ",2014-02-05 06:42:00-05:00,INCY,positive
665275.0,Adam Feuerstein Tweet: '$INCY — JMP's Liisa Bayko says CEO Friedman's retirement was expected',2014-01-13 09:47:00-05:00,INCY,neutral
665276.0,Incyte Names Hervé Hoppenot President and CEO,2014-01-13 05:49:00-05:00,INCY,neutral
665277.0,"Nomura Initiates Coverage on Incyte Corporation at Buy, Announces $68.00 PT",2014-01-08 07:47:00-05:00,INCY,neutral
665278.0,Incyte Reports Jakafi Data Continues to Show Improved Overall Survival for Patients with Myelofibrosis at ASH ,2013-12-09 12:48:00-05:00,INCY,positive
665279.0,UPDATE: Piper Jaffray Initiates Coverage on Incyte as 2014 Biotech Sector Outlook Remains Strong,2013-11-27 11:16:00-05:00,INCY,positive
665280.0,Piper Jaffray Reinstates Overweight on Incyte Corporation,2013-11-26 16:22:00-05:00,INCY,negative
665281.0,Incyte Completes Offering of $750M of Convertible Senior Notes ,2013-11-14 16:15:00-05:00,INCY,neutral
665282.0,Geron Revealed Positive Imetelstat Results Amidst Data Concerns,2013-11-07 13:10:00-05:00,INCY,positive
665283.0,Incyte Corporation Reports Q3 EPS of $(0.14) vs $(0.13) Est; Revenue of $85.10M vs $81.37M Est,2013-10-31 07:19:00-04:00,INCY,neutral
665284.0,Incyte Announces Positive Phase II Clinical Trial Results of Oral JAK1 Inhibitor in Patients with Active RA,2013-10-28 22:43:00-04:00,INCY,positive
665285.0,Incyte Reports Positive Results from Phase II Clinical Trial of Oral JAK1 Inhibitor,2013-10-03 06:03:00-04:00,INCY,positive
665286.0,"Barclays Maintains Equal-weight on Incyte Corporation, Raises PT to $36.00",2013-09-20 10:21:00-04:00,INCY,neutral
665287.0,UPDATE: Jefferies Raises PT on Incyte Following Favorable Phase 2 RECAP Data,2013-08-22 11:44:00-04:00,INCY,positive
665288.0,"Jefferies Maintains Buy on Incyte Corporation, Raises PT to $44.00",2013-08-22 07:47:00-04:00,INCY,neutral
665289.0,Benzinga Market Wrap For August 21: FOMC Minutes Send Markets Spinning,2013-08-21 16:24:00-04:00,INCY,neutral
665290.0,Mid-Afternoon Market Update: Retailers Hurting As Lowe's Rises,2013-08-21 15:47:00-04:00,INCY,negative
665291.0,Mid-Day Market Update: Staples Shares Slip On Weak Earnings,2013-08-21 12:52:00-04:00,INCY,negative
665292.0,UPDATE: Canaccord Raises PT on Incyte Following Phase 2 RECAP Data Release,2013-08-21 11:42:00-04:00,INCY,neutral
665293.0,UPDATE: Bank of America Raises PT on Incyte on Compelling New Data,2013-08-21 11:31:00-04:00,INCY,positive
665294.0,Hearing Morgan Stanley Cautious on Incyte,2013-08-21 11:20:00-04:00,INCY,negative
665295.0,Mid-Morning Market Update: Markets Mostly Lower; Lowe's Posts Upbeat Profit,2013-08-21 10:30:00-04:00,INCY,positive
665296.0,Stocks Hitting 52-Week Highs,2013-08-21 10:12:00-04:00,INCY,neutral
665297.0,Benzinga's Top Pre-Market Gainers,2013-08-21 08:09:00-04:00,INCY,positive
665298.0,UPDATE: Incyte Shares Rise 19% Pre-Market on Positive Top-Line Results of Phase II PoC Trial of Ruxolitinib,2013-08-21 07:43:00-04:00,INCY,positive
665299.0,"Incyte Issues Top-Line Results of Phase II PoC Trial of Ruxolitinib, Showed Hazard Ratio of 0.79",2013-08-21 07:04:00-04:00,INCY,neutral
665300.0,UPDATE: UBS Investment Research Raises PT on Incyte Following 2Q13 Results,2013-08-02 11:09:00-04:00,INCY,neutral
665301.0,"UBS Maintains Buy on Incyte Corporation, Raises PT to $28.00",2013-08-02 09:04:00-04:00,INCY,neutral
665302.0,"Oppenheimer Maintains Outperform on Incyte Corporation, Raises PT to $28.00",2013-08-02 08:39:00-04:00,INCY,neutral
665303.0,Incyte Corporation Reports Q2 EPS of $(0.02) Which May Not Compare $0.08 Est; Revenue of $101.70M Which May Not Compare $114.34M Est,2013-08-01 18:00:00-04:00,INCY,neutral
665304.0,Bernstein Believes Onyx Pharma Bid Would Need to be in $140-150/Share Range to Sufficiently Entice Management,2013-07-01 12:38:00-04:00,INCY,neutral
665305.0,UPDATE: Oppenheimer Reiterates Overweight on Incyte as Jakafi Profile Continues to Improve,2013-06-17 15:30:00-04:00,INCY,positive
665306.0,Piper Jaffray Reiterates Overweight Rating on Incyte Following 3-Year Survival Data Presentation,2013-06-17 12:21:00-04:00,INCY,negative
665307.0,A Peek Into The Market Before The Trading Starts,2013-06-13 07:18:00-04:00,INCY,neutral
665308.0,"Lilly, Incyte Announce Baricitinib Efficacy and Safety Data from Phase 2b JADA Study in Patients with Rheumatoid Arthritis ",2013-06-13 06:05:00-04:00,INCY,positive
665309.0,Incyte Says FDA Updates Prescribing Info for Jakafi,2013-06-12 17:16:00-04:00,INCY,neutral
665310.0,Hearing Negative Morgan Stanley Note on Incyte,2013-06-11 13:12:00-04:00,INCY,negative
665311.0,Incyte Presents Phase I Trial Results of INCB024360 at ASCO ,2013-06-01 14:32:00-04:00,INCY,neutral
665312.0,Incyte Exec Speaking at UBS Healthcare Conference: Calls Pipeline of Products 'Promising' Over Short Term,2013-05-20 14:32:00-04:00,INCY,neutral
665313.0,"Goldman Sachs Reinstates Sell on Incyte Corporation, Announces $17.00 PT",2013-05-07 06:45:00-04:00,INCY,neutral
665314.0,Incyte Corporation Reports Q1 EPS of $(0.12) vs $(0.20) Est; Revenue of $71.10M vs $68.16M Est,2013-05-02 07:42:00-04:00,INCY,neutral
665315.0,Incyte Wins $25M Milestone as c-MET Inhibitor INC280 Moves Into Phase II Trial,2013-04-29 08:02:00-04:00,INCY,positive
665316.0,"Jefferies Reiterates Buy Rating, $36 PT on Incyte Corporation Despite PML Case",2013-03-18 13:45:00-04:00,INCY,neutral
665317.0,UPDATE: JP Morgan Reiterates Incyte Corporation at Overweight Following PML Case,2013-03-18 13:42:00-04:00,INCY,neutral
665318.0,"Mid-Day Market Update: Markets Trim Losses, Incyte Drops",2013-03-18 12:44:00-04:00,INCY,negative
665319.0,"Mid-Morning Market Update: Markets Tumble, Cynosure To Acquire Palomar",2013-03-18 10:29:00-04:00,INCY,neutral
665320.0,"From 8-K: Incyte Reports Case of PML in 75 Year Old Male Patient from UK, Treated with Ruxolitinib",2013-03-18 07:59:00-04:00,INCY,neutral
665321.0,"From 8-K: Incyte Reports Case of PML in 75 Year Old Male Patient from UK, Treated with Ruxolitinib",2013-03-18 07:50:00-04:00,INCY,neutral
665322.0,"Jefferies Maintains Buy on Incyte Corporation, Lowers PT to $36.00",2013-02-15 07:30:00-05:00,INCY,negative
665323.0,Incyte Corporation Sees FY2013 Sales $210.0M-225.0M vs $223.0M Est,2013-02-14 07:37:00-05:00,INCY,neutral
665324.0,Incyte Corporation Reports Q4 EPS of $0.14 vs $(0.02) Est; Revenue of $113.80M vs $92.03M Est,2013-02-14 07:37:00-05:00,INCY,neutral
665325.0,Incyte Shares Sink Following Morgan Stanley's Downgrade to Underweight,2013-01-23 09:39:00-05:00,INCY,positive
665326.0,Lazard Capital Markets Upgrades Incyte Corporation to Buy,2013-01-14 08:40:00-05:00,INCY,neutral
665327.0,Lazard Capital Markets Upgrades Incyte Corporation to undefined,2013-01-14 08:39:00-05:00,INCY,neutral
665328.0,Mid-Afternoon Market Update: Bernanke Press Conference Leads to Drop in the Markets,2012-12-12 15:56:00-05:00,INCY,negative
665329.0,"Mid-Day Market Update: Fed to Continue Stimulus, Markets Rise",2012-12-12 14:26:00-05:00,INCY,neutral
665330.0,"Bank of America Merrill Lynch Reiterates Buy Rating, $25 PT on Incyte Corporation",2012-12-12 11:36:00-05:00,INCY,neutral
665331.0,Mid-Morning Market Update: Markets Flat in Anticipation of FOMC Statement,2012-12-12 10:51:00-05:00,INCY,positive
665332.0,Incyte Achieves $50 Million Milestone as Oral JAK1/JAK2 Inhibitor Baricitinib Advances into Phase III Development for Rheumatoid Arthritis  ,2012-11-15 08:03:00-05:00,INCY,negative
665333.0,"Lilly and Incyte Announce Additional Phase IIb Baricitinib Data, Advance into Phase III Trials",2012-11-13 16:05:00-05:00,INCY,neutral
665334.0,"UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on Incyte Corporation",2012-11-07 11:06:00-05:00,INCY,neutral
665335.0,"Jefferies & Company Maintains Incyte Genomics at Buy, Raises PT from $31 to $37",2012-11-07 07:06:00-05:00,INCY,neutral
665336.0,"Morgan Stanley Maintains Incyte Genomics at Equal-weight, Lowers PT from $15 to $14",2012-11-01 15:25:00-04:00,INCY,negative
665337.0,"Bank of America Maintains Incyte Genomics at Buy, Lowers PO from $26 to $25",2012-11-01 15:22:00-04:00,INCY,negative
665338.0,Incyte Genomics Reports Q3 EPS $-0.17 vs $-0.21 Est; Revenues $60.5M vs $60.61M Est,2012-11-01 09:28:00-04:00,INCY,neutral
665339.0,Jim Daly to Join Incyte as Executive Vice President and Chief Commercial Officer  ,2012-10-22 08:04:00-04:00,INCY,positive
665340.0,"UPDATE: Bank of America Merrill Lynch Reiterates Buy Rating, Lowers PT on Incyte Corporation",2012-09-05 10:26:00-04:00,INCY,negative
665341.0,"Bank of America Maintains Incyte Genomics at Buy, Lowers PO from $26 to $24",2012-09-05 07:05:00-04:00,INCY,negative
665342.0,Incyte's Chief Commericial Officer Will Leave Company,2012-08-29 16:32:00-04:00,INCY,negative
665343.0,"Bank of America Maintains Incyte Genomics at Buy, Lowers PO from $28 to $26",2012-08-07 14:32:00-04:00,INCY,negative
665344.0,Benzinga's Top Initiations,2012-08-07 07:31:00-04:00,INCY,positive
665345.0,Incyte Spiking Higher,2012-08-06 12:19:00-04:00,INCY,neutral
665346.0,"Morgan Stanley Maintains Incyte Genomics at Equal-weight, Lowers PT from $16 to $15",2012-08-03 14:56:00-04:00,INCY,negative
665347.0,"Barclays Maintains Incyte Genomics at Equal-weight, Lowers PT from $24 to $21",2012-08-03 14:18:00-04:00,INCY,negative
665348.0,Incyte Genomics Reports Q2 EPS $0.03 vs $0.00 Est; Revenues $86.5M vs $84.56M Est,2012-08-02 08:41:00-04:00,INCY,neutral
665349.0,Incyte Genomics Reports Q2 EPS $0.03 vs $0.00 Est; Revenues $86.5M vs $84.56M Est,2012-08-02 07:08:00-04:00,INCY,neutral
665350.0,"Social Media Outlook for Tuesday July 3 (INCY, MCS, CLNE, OPEN)",2012-07-03 13:10:00-04:00,INCY,neutral
665351.0,Piper Jaffray Recommends Incyte (INCY),2012-06-08 14:59:00-04:00,INCY,positive
665352.0,"Lilly and Incyte's Oral JAK1 and JAK2 Inhibitor, Baricitinib, Showed Positive Results in Phase IIb Study in Patients with Active Rheumatoid Arthritis ",2012-06-08 10:47:00-04:00,INCY,positive
665353.0,Incyte Presents Results from a Phase I Trial of INCB024360; Achieves Greater Than 90% IDO1 Inhibition at Generally Well-tolerated Doses ,2012-06-04 16:07:00-04:00,INCY,neutral
665354.0,"The Definitive Biotech ETF Guide (IBB, XBI, FBT)",2012-05-21 13:35:00-04:00,INCY,neutral
665355.0,"S&P Bullish On Biotech ETFs (FBT, IBB, XBI)",2012-05-15 14:31:00-04:00,INCY,neutral
665356.0,"Benzinga's Top Upgrades with Color for May 11, 2012",2012-05-11 12:58:00-04:00,INCY,positive
665357.0,UPDATE: Goldman Sachs Upgrades Incyte; Raises PT,2012-05-11 08:12:00-04:00,INCY,neutral
665358.0,Benzinga's Top Upgrades,2012-05-11 07:38:00-04:00,INCY,positive
665359.0,"Goldman Sachs Upgrades Incyte Genomics from Neutral to Buy, Raises PT from $21 to $29",2012-05-11 06:41:00-04:00,INCY,neutral
665360.0,"UBS Maintains Incyte Genomics at Buy, Raises PT from $22 to $26",2012-04-27 10:44:00-04:00,INCY,neutral
665361.0,"Bank of America Maintains Incyte Genomics at Buy, Raises PO from $23 to $25",2012-04-26 14:26:00-04:00,INCY,negative
665362.0,"JP Morgan Maintains Incyte Genomics at Overweight, Raises PT from $23 to $25",2012-04-26 14:26:00-04:00,INCY,neutral
665363.0,"Canaccord Maintains Incyte Genomics at Buy, Raises PT from $22 to $25",2012-04-26 14:05:00-04:00,INCY,neutral
665364.0,"Brean Murray Carret & Co. Maintains Incyte Genomics at Buy, Raises PT from $23 to $28",2012-04-26 12:54:00-04:00,INCY,neutral
665365.0,Incyte Genomics Reports Q1 EPS $-0.36 vs $-0.46 Est; Revenues $36.2M vs $25.32M Est,2012-04-26 08:17:00-04:00,INCY,neutral
665366.0,Incyte Announces EU Regulatory Milestone for Ruxolitinib   ,2012-04-20 09:25:00-04:00,INCY,neutral
665367.0,"Canaccord Initiates Coverage on Incyte Genomics at Buy, Announces PT of $22",2012-03-26 08:56:00-04:00,INCY,neutral
665368.0,UPDATE: Jefferies Raises Target on Incyte to $31,2012-02-16 07:05:00-05:00,INCY,neutral
665369.0,"Morgan Stanley Downgrades Incyte Genomics from Overweight to Equal-weight, Announces PT of $16",2012-02-16 06:22:00-05:00,INCY,negative
665370.0,"Brean Murray Carret & Co. Maintains Incyte Genomics at Buy, Lowers PT from $25 to $23",2012-02-15 12:50:00-05:00,INCY,negative
665371.0,Piper Jaffray Maintains Overweight on Incyte ,2012-02-15 10:57:00-05:00,INCY,negative
665372.0,Collins Stewart: Incyte's Jakafi Knocks 4Q Sales Out of the Park,2012-02-15 10:34:00-05:00,INCY,negative
665373.0,Incyte Genomics Reports Q4 EPS $(0.44) vs $(0.39) Est; Revenues $28.90M vs $25.65M Est	 		,2012-02-15 07:11:00-05:00,INCY,neutral
665374.0,Notable Call Options Activity in Incyte,2012-01-26 10:40:00-05:00,INCY,neutral
665375.0,UPDATE: Bank of America Reports Development of New Incyte Model; Lowers PT,2012-01-23 09:42:00-05:00,INCY,negative
665376.0,"Benzinga's M&A Chatter for Tuesday January 17, 2012",2012-01-17 20:00:00-05:00,INCY,neutral
665377.0,"Incyte Spokesperson Acknowledges Earlier MSN Money Article as Source of Takeover Rumor, But Had No Further Comments",2012-01-17 14:31:00-05:00,INCY,negative
665378.0,Positive Rumors Circulate About Incyte Genomics,2012-01-17 10:18:00-05:00,INCY,positive
665379.0,Incyte Spiking Higher; May be Attributed to Takeover Chatter,2012-01-17 10:18:00-05:00,INCY,neutral
665380.0,JPMorgan Confab Kicks Off Biotech 2012,2012-01-05 11:46:00-05:00,INCY,neutral
665381.0,Incyte Spokesperson Says Nothing New to Report; Stock Price Spiked Nearly 4%,2011-12-21 12:55:00-05:00,INCY,neutral
665382.0,"Incyte Corporation Spiking Higher on Heavy Volume, Hearing Takeover Chatter",2011-12-21 12:45:00-05:00,INCY,neutral
665383.0,"Benzinga's M&A Chatter for Thursday December 15, 2011",2011-12-15 17:47:00-05:00,INCY,neutral
665384.0,"Jefferies Reiterates Buy, $27 Target on Incyte ",2011-12-14 06:59:00-05:00,INCY,neutral
665385.0,Morgan Stanley Reiterates Overweight On Incyte,2011-12-13 12:57:00-05:00,INCY,negative
665386.0,"Piper Jaffray Maintains Overweight, $23 Target on Incyte ",2011-12-13 10:30:00-05:00,INCY,negative
665387.0,Benzinga's Volume Gainers,2011-12-12 15:28:00-05:00,INCY,neutral
665388.0,"First FDA-Approved Treatment for Myelofibrosis, Jakafi, Discussed in Multiple Presentations at 2011 ASH Annual Meeting   ",2011-12-12 08:31:00-05:00,INCY,neutral
665389.0,Jefferies Maintains Buy Rating on Incyte,2011-12-12 07:12:00-05:00,INCY,neutral
665390.0,Five Biotech Stocks to Watch Going into Big Doctors' Meeting,2011-12-09 13:06:00-05:00,INCY,neutral
665391.0,UPDATE Citi Lowers Price Target on Incyte to $15,2011-12-05 07:02:00-05:00,INCY,negative
665392.0,"Citigroup Downgrades Incyte Corporation to Neutral, PT Lowered to $15",2011-12-05 06:11:00-05:00,INCY,negative
665393.0,Seven Stocks Insiders Are Buying,2011-12-02 14:12:00-05:00,INCY,neutral
665394.0,Incyte Genomics Hits 52-Week Low of $11.91,2011-11-23 11:07:00-05:00,INCY,negative
665395.0,Incyte Genomics Hits 52-Week Low of $11.99,2011-11-21 09:31:00-05:00,INCY,negative
665396.0,Incyte Genomics Hits 52-Week Low of $12.31,2011-11-18 11:09:00-05:00,INCY,negative
665397.0,Will Incyte's Blood Cancer Drug Bring Dividends?,2011-11-18 10:27:00-05:00,INCY,negative
665398.0,Goldman Sachs Maintains Neutral on Incyte Following Jakafi Approval by FDA,2011-11-16 12:47:00-05:00,INCY,positive
665399.0,"Incyte Receives Approval from FDA, JP Morgan Maintains Overweight",2011-11-16 12:29:00-05:00,INCY,positive
665400.0,Trading Resumes in Incyte,2011-11-16 11:47:00-05:00,INCY,neutral
665401.0,PREVIEW: Incyte to Resume Trading at 11:45am,2011-11-16 11:28:00-05:00,INCY,neutral
665402.0,FDA Approves First Drug to Treat a Rare Bone Marrow Disease,2011-11-16 11:08:00-05:00,INCY,positive
665403.0,Incyte Halted; Pending News,2011-11-16 11:02:00-05:00,INCY,neutral
665404.0,"Incyte Hits New 52-Week Low, $12.51",2011-11-11 11:15:00-05:00,INCY,negative
665405.0,Incyte Corp Reports Q3 EPS $(0.42) vs $(0.45) Est; Revenues $16.8M vs $16.54M Est			,2011-10-27 07:12:00-04:00,INCY,neutral
665406.0,Oppenheimer Has Outperform On Incyte,2011-09-15 09:23:00-04:00,INCY,neutral
665407.0,A Peek Into The Market Before The Trading Starts,2011-08-03 07:31:00-04:00,INCY,neutral
665408.0,Incyte Corporation Announces FDA Accepts NDA Filing for Ruxolitinib as a Treatment for Myelofibrosis   ,2011-08-03 07:00:00-04:00,INCY,positive
665409.0,Tuesday's Put/Call Ratio Leaders,2011-07-26 12:28:00-04:00,INCY,neutral
665410.0,Jefferies Reports Incyte's Positive Feedback on Ruxolitinib at EHA,2011-06-13 07:28:00-04:00,INCY,positive
665411.0,Piper Jaffray Initiates an Overweight Rating and $23 PT on Incyte ,2011-06-10 07:20:00-04:00,INCY,negative
665412.0,"Piper Jaffray Initiates Incyte Corporation At Overweight, $23 PT",2011-06-10 06:09:00-04:00,INCY,negative
665413.0,Jefferies Comments on Incyte's Presentation at the 2011 Global Healthcare Conference,2011-06-09 07:40:00-04:00,INCY,neutral
665414.0,Jefferies & Company Reports on Incyte,2011-06-07 08:24:00-04:00,INCY,neutral
665415.0,Brean Murray Carret Increases Price Target On Incyte To $25,2011-06-07 08:14:00-04:00,INCY,neutral
665416.0,J.P. Morgan Reiterates Rating On INCY Following ASCO,2011-06-07 07:51:00-04:00,INCY,neutral
665417.0,Brean Murray Raises PT On Incyte Corporation To $25,2011-06-07 06:36:00-04:00,INCY,neutral
665418.0,Oppenheimer Comments on Incyte ,2011-06-06 08:38:00-04:00,INCY,neutral
665419.0,Incyte Submits New Drug Application for Ruxolitinib in Myelofibrosis to the US Food and Drug Administration,2011-06-06 08:05:00-04:00,INCY,neutral
665420.0,Goldman Sachs Initiates Coverage of Incyte Corporation with Neutral and PT of $20,2011-06-02 09:33:00-04:00,INCY,neutral
665421.0,"Goldman Initiates INCY At Neutral, $20 PT",2011-06-02 06:27:00-04:00,INCY,neutral
665422.0,Jefferies Maintains Buy on Incyte,2011-05-31 07:14:00-04:00,INCY,neutral
665423.0,UPDATE: Oppenheimer Raises PT on Incyte to $25 (INCY),2011-05-19 07:58:00-04:00,INCY,neutral
665424.0,"Incyte Vice President Sells 100,000 Shares at $20.24 for over $2M Proceeds",2011-05-11 16:21:00-04:00,INCY,positive
665425.0,"NASDAQ Stocks Hitting 52-Week Highs (CGNX, IPGP, INCY, OBAF)",2011-05-03 10:10:00-04:00,INCY,neutral
665426.0,Incyte Reports Q1 EPS of $(0.21) vs. $(0.32) Estimate; Revenues $32M vs. $19.51M Estimate (INCY),2011-05-03 07:08:00-04:00,INCY,neutral
665427.0,Negative Rumors About INCYTE Circulate (INCY),2011-04-21 14:01:00-04:00,INCY,negative
665428.0,Brean Murray Carret Comments On Incyte's CYT387,2011-04-20 07:34:00-04:00,INCY,neutral
665429.0,Options Brief: Incyte Corporation (INCY),2011-04-15 11:06:00-04:00,INCY,neutral
665430.0,Incyte Achieves $15 Million Milestone for c-MET Inhibitor Oncology Program   ,2011-04-05 07:32:00-04:00,INCY,negative
665431.0,Incyte 4th Qtr Revenue Surges To $86 Million (INCY) ,2011-02-10 07:45:00-05:00,INCY,neutral
665432.0,Incyte Reports Q4 EPS of $0.24,2011-02-10 07:10:00-05:00,INCY,neutral
665433.0,Jefferies Update From Meeting With INCY Management,2011-01-12 09:55:00-05:00,INCY,neutral
665434.0,INCY's INC424 Meets Goal - Analyst Blog,2010-12-22 11:33:00-05:00,INCY,neutral
665435.0,INCY's INC424 Meets Goal - Analyst Blog,2010-12-22 11:15:00-05:00,INCY,neutral
665436.0,Incyte Climbs 8.2% After Its Drug Meets Goals (INCY),2010-12-21 16:51:00-05:00,INCY,neutral
665437.0,"Benzinga's Volume Movers (MATK, CMED, INCY, AMED)",2010-12-21 10:44:00-05:00,INCY,neutral
665438.0,Options Brief: Incyte Corporation (INCY),2010-12-21 10:44:00-05:00,INCY,neutral
665439.0,J.P. Morgan maintains Overweight Rating on Incyte Corporation (INCY),2010-12-21 08:41:00-05:00,INCY,negative
665440.0,"Benzinga's Top Pre-Market NASDAQ Gainers (LCRD, MATK, INCY, ADBE)",2010-12-21 08:12:00-05:00,INCY,positive
665441.0,Oppenheimer Says Incyte Will Outperform (INCY),2010-12-21 07:55:00-05:00,INCY,neutral
665442.0,Incyte Up 5% In Post-Market On Phase III Data (INCY),2010-12-20 16:24:00-05:00,INCY,neutral
665443.0,"Benzinga's Top Pre-Market NASDAQ Gainers (INCY, APSG, ITMN, SPPI)",2010-12-20 08:14:00-05:00,INCY,positive
665444.0,Neutral on Incyte - Analyst Blog,2010-12-03 17:00:00-05:00,INCY,neutral
665445.0,Neutral on Incyte - Analyst Blog,2010-12-03 16:17:00-05:00,INCY,neutral
665446.0,Incyte Buoyed By Strong Rev. - Analyst Blog,2010-11-15 13:06:00-05:00,INCY,positive
665447.0,Jefferies Has Buy Rating On Incyte (INCY),2010-11-12 07:50:00-05:00,INCY,neutral
665448.0,J.P. Morgan Reiterates Incyte Corporation Rating,2010-11-11 08:33:00-05:00,INCY,neutral
665449.0,Incyte Corporation's Efficacy Improves,2010-11-11 08:16:00-05:00,INCY,positive
665450.0,Oppenheimer Raises Price Target On Incyte,2010-10-01 07:30:00-04:00,INCY,neutral
665451.0,"Zacks.com featured expert Kevin Matras highlights: Orient-Express Hotels Ltd., Incyte Corp., Dana Holding Corp., Toreador Resources Corp. and UAL Corp. - Press Releases",2010-09-28 19:48:00-04:00,INCY,neutral
665452.0,"Incyte, FDA Agree on Study Design - Analyst Blog",2010-09-16 18:03:00-04:00,INCY,positive
665453.0,Incyte Evenly Poised - Analyst Blog,2010-08-30 13:03:00-04:00,INCY,positive
665454.0,"Oppenheimer Likes Incyte, Sees 40% Upside (INCY)",2010-08-26 07:45:00-04:00,INCY,positive
665455.0,Incyte Corp Draws Bull Action After Earnings,2010-05-06 11:15:00-04:00,INCY,neutral
665456.0,Incyte Corp Draws Bull Action After Earnings,2010-05-06 11:15:00-04:00,INCY,neutral
665457.0,Top Stocks of Delaware,2010-04-12 14:28:00-04:00,INCY,positive
665458.0,Jefferies & Company Raises Incyte (INCY) Target Price To $19,2010-03-23 09:28:00-04:00,INCY,neutral
665459.0,How Will Obama-Care Play Into The Markets And ETFs?,2010-03-21 21:50:00-04:00,INCY,positive
665460.0,Leerink Swann Reiterates Incyte (INCY) Outperform Rating,2010-03-17 11:41:00-04:00,INCY,neutral
665461.0,"Mad Money Lightning Round: Jim Recommends ERTS, INCY, MNRO, CTSH, GST, CREE, GLW, NFLX",2010-03-11 08:07:00-05:00,INCY,negative
665462.0,Eli Lilly (LLY) Lacks Near Term Upside Drivers,2009-12-22 13:07:00-05:00,INCY,neutral
665463.0,"Top Gainers in NASDAQ (CHTT, BUCY, INCY, SBLK, MAIL)",2009-12-21 12:54:00-05:00,INCY,positive
665464.0,"Benzinga’s Top Pre- Market Gainers (CHTT, BUCY, SGEN, INCY, MAIL, ATHX)",2009-12-21 08:25:00-05:00,INCY,positive
665465.0,"Benzinga’s Top Gainers (RTK, INCY, HEV, QADI, JDSU)",2009-11-25 12:30:00-05:00,INCY,positive
665466.0,"Benzinga’s Top Pre- Market Gainers (TIF, RFMD, AIXG, INCY, SOLF, QGEN, CYTX, SVA)",2009-11-25 08:40:00-05:00,INCY,positive
665467.0,"Benzinga’s Top Upgrades (WAT, PMTC, DWA, INCY)",2009-10-28 10:34:00-04:00,INCY,positive
665468.0,"Stocks to Watch (STX,FUL,GIS,ATPG,INCY,DAC)",2009-09-23 05:27:00-04:00,INCY,neutral
